Reaxys NDF Azithromycin

Query
Query
OH O O HO O O HO HO O O N
Results
Date
1. Query
51 reactions
2011-04-19 08h:55m:34s (EST)
O OH
Search as: Product, As drawn, No salts, No mixtures
Copyright 2011 Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys is a trademark owned and protected by Elsevier Properties SA and used under license.
1/55
2011-04-19 08:56:52
HN N HO OH O
O
N N HO OH OH HO
OH HO
O O O O OH
O O O O
O OH
Rx-ID: 23057466 View in Reaxys Yield 87 % Conditions & References Example Name 1C Example 1C; Preparation of Azithromycin dihydrate; To the 300 ml of acetone, 100 gm 9-Deoxo-9a-aza-9a-homoerythromycin A (prepared according to Example IB) was added. The mixture of 17.49 ml of formic acid and 17.49 ml of formaldehyde was EPO <DP n="14"/>prepared. This mixture was added to 9-Deoxo-9a-aza-9a-homoerythromycin A solution within 5 to 6 hours at 40.deg. C. The reaction was monitored for 2 hours at 40.deg. to 45.deg. C. The pH of the reaction mixture was adjusted to 11 to 11.5 by adding sodium hydroxide solution. The charcoal treatment was given to reaction mixture. The acetone layer was separated from the reaction mixture. To the acetone layer, 650 ml water was added within 12 hour while stirring. The mixture was stirred at 20.deg. C for 12 hours. After the completion of reaction, Azithromycin dihydrate was filtered and washed with water. Azithromycin dihydrate was dried at 65.deg. C. The yield and purity of the Azithromycin dihydrate was 87 percent and 98 percent. Stage 1: With formic acid in acetone, Time= 7 - 8h, T= 40 - 45 C Stage 2: With sodium hydroxide in water, acetone, pH= 11 - 11.5 Patent; KOPRAN RESEARCH LABORATORIES LTD; WO2007/15265; (2007); (A2) English View in Reaxys 77 % Example Name 5 6.48 g of a compound of formula III obtained according to example 4 are dissolved in 58 ml of ethyl acetate and 0.6 ml of formic acid and 1.30 ml of 37percent aqueous formaldehyde are added to the solution obtained. The mixture obtained is refluxed for ca. 2 hours. HPLC analysis shows the formation of azithromycin. [00106] Yield: 77percent.of theory. With formic acid in water, ethyl acetate, Time= 2h, Heating / reflux Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys 71 % With formic acid in chloroform, water, Time= 2h, T= 70 C , Inert atmosphere, Eschweiler-Clarke reaction Glansdorp, Freija G.; Spandl, Richard J.; Spring, David R.; Swatton, Jane E.; Welch, Martin; Loiseleur, Olivier; Organic and Biomolecular Chemistry; vol. 6; nb. 22; (2008); p. 4120 - 4124 View in Reaxys Example Title Example - Preparation of azithromycin Monohydrate Example - Preparation of azithromycin Monohydrate 9-Deoxo-9a-aza-9a-homoerythromycin A (73.5g - 0.1 mole) was dissolved in 250 ml acetonitrile.. To this solution, formic acid (19 ml, 0.5 mole) followed by formaldehyde (37percent, 20 ml, 0.25 mole) were added and refluxed for 24 hours.. The PH of the reaction mixture was adjusted with alkali (NaOH solution) to 10.5 and filtered to remove particles.. To the filtered acetonitrile solution, an equal volume of water was added to precipitate azithromycin monohydrate as cube shaped crystals.. The crystals were filtered and dried under vacuum at 50.deg.C to give 65g of azithromycin monohydrate having water content of 5percent (water content measured by the Karl Fischer titration method).. This sample of azithromycin monohydrate crystals has a characteristic solid state (KBr pellet) IR spectrum (Fig 1) and a characteristic X-ray diffraction pattern (Fig 2). In the process described above reductive methylation is carried out in acetonitrile (solvent) and Azithromycin monohydrate crystals are directly precipitated from the reaction mixture without the need for conducting any extraction procedure. All patent, patent applications, articles, publications, textbooks and any other references cited in this application are incorporated herein by reference in their entirety for all purposes.
2/55
2011-04-19 08:56:52
Stage 1: With formic acid in water, acetonitrile, Time= 24h, Heating / reflux Stage 2: With sodium hydroxide in water, acetonitrile, pH= 10.5 Patent; Alembic Limited; EP1400528; (2004); (A1) English View in Reaxys Example Name 2 Example Title Preparation of Crude Azithromycin Azaerythromycin (100 kg) (Ercros Ind., Madrid, Spain) and 95percent ethanol (500 L) were combined to form a mixture in a 1,000-L reaction vessel. The mixture was then stirred. Paraformaldehyde (10.4 kg) and formic acid (15 kg) were added, and the mixture was heated at a reflux temperature (i.e., 78.deg. C.) for about 4 hours. When thin-layer chromatography (TLC) indicated the disappearance of azaerythromycin, about 200 L of ethanol was removed by distillation under vacuum. At about 25-30.deg. C., water (300 kg) and 25percent ammonium hydroxide (40 kg) were added to bring the pH to above 9. Then, more water (300 kg) was added. The mixture was further stirred at room temperature for about 6 hours. The precipitate was filtered and washed with water, providing about 105 kg of crude, wet azithromycin (contained 24.74percent water (w/w)). With formic acid in ethanol, Time= 4h, T= 78 C , Industry scale Patent; Gutman, Daniella; Shahal, Leah; US2006/63725; (2006); (A1) English View in Reaxys Example Name 2.2 (b); The pH of the chloroform extract was adjusted to 5.0 to 5.5 with formic acid (17.0 g) and formaldehyde (17.0 g) and the resultant mixture was refluxed for 10 hr. After completion of the reaction, water (500 ml) was added and pH brought to 4.0 with hydrochloric acid. The pH of the reaction mixture was adjusted to 8.0 using sodium hydroxide solution and the aqueous layer was extracted with chloroform. The chloroform extract was concentrated to dryness. The residue obtained was dissolved <n="13"/>in methylene chloride (750.0 ml), filtered and concentrated ana dried under reduced pressure. The solid so obtained was dissolved in acetonitrile (750.0 ml). The acetonitrile was partially distilled out (600.0 ml) under vaccum. The slurry obtained was cooled to 10-25.deg.C and filtered to get anhydrous azithromycin. Yield: 45.0 g. Purity: 99.0 percent. Stage 1: With formic acid in chloroform, Time= 10h, pH= 5 - 5.5, Heating / reflux Stage 2: With hydrogenchloride in water, pH= 4 Stage 3: With sodium hydroxide, pH= 8, Product distribution / selectivity Patent; WOCKHARDT LTD; PUROHIT, Manish; MUKARRAM, Siddiqui Mohammad Jaweed; NAITHANI, Pankaj Kumar; POKALWAR, Raj Kumar; SUTARIYA, Prakash Maganlal; WO2007/80507; (2007); (A2) English View in Reaxys Example Name 4 Example 4: Preparation of azithromycin; The Cyclic amine of formula III obtained from example 1, was dissolved in chloroform (1 Litre) and adjusted to pH 5.0 to 5.5 with methylating mixture i.e. formic acid (17.0 g) and formaldehyde (17.0 g) and refluxed for 10 hr. The resultant mass was subjected to process as exemplified in example 3 (b), to get the title compound. With formic acid in chloroform, Time= 10h, pH= 5 - 5.5, Heating / reflux, Product distribution / selectivity Patent; WOCKHARDT LTD; PUROHIT, Manish; MUKARRAM, Siddiqui Mohammad Jaweed; NAITHANI, Pankaj Kumar; POKALWAR, Raj Kumar; SUTARIYA, Prakash Maganlal; WO2007/80507; (2007); (A2) English View in Reaxys Example Name 3 Example-3; [100][101] Preparation of Azithromycin; [102][103] 9-Deoxo-9a-aza-9a-homoerythromycin A (III) (73.5g) was dissolved in acetone(250ml). To this solution formic acid (19ml) followed by formaldehyde (37percent, 20ml) were added and refluxed for 24 hrs. The pH of the reaction mixture was adjusted with alkali to 10.5 and filtered to remove particles. To the filtered acetone solution equal volume of water was added to precipitate azithromycin (IV). The crystals were filtered and dried under vacuum at 5O0C to give the title product (65g).
3/55
2011-04-19 08:56:52
Stage 1: With formic acid in acetone, Time= 24h, Reflux Stage 2: in acetone, pH= 10.5, Alkaline solution Patent; ALEMBIC LIMITED; WO2009/156938; (2009); (A2) English View in Reaxys
HN N HO OH O
O
OH HO
HO
O O O O OH O
OH O O O O
OH O OH N 2 H O H
O OH
Rx-ID: 23233586 View in Reaxys Yield 87 % Conditions & References Example Name 1C To the 300 ml of acetone, 100 gm 9-Deoxo-9a-aza-9a-homoerythromycin A (prepared according to Example IB) was added. The mixture of 17.49 ml of formic acid and 17.49 ml of formaldehyde was prepared. This mixture was added to 9-Deoxo-9a-aza-9a-homoerythromycin A solution within 5 to 6 hours at 40.deg. C. The reaction was monitored for 2 hours at 40.deg. to 45.deg. C. The pH of the reaction mixture was adjusted to 11 to 11.5 by adding sodium hydroxide solution. The charcoal treatment was given to reaction mixture. The acetone layer was separated from the reaction mixture. To the acetone layer, 650 ml water was added within 12 hour while stirring. The mixture was stirred at 20.deg. C for 12 hours. After the completion of reaction, Azithromycin dihydrate was filtered and washed with water. Azithromycin dihydrate was dried at 65.deg. C. The yield and purity of the Azithromycin dihydrate was 87 percent and 98 percent. Stage 1: With formic acid in acetone, Time= 7 - 8h, T= 40 - 45 C Stage 2: With sodium hydroxide in water, acetone, pH= 11 - 11.5 Stage 3: With water in acetone, Time= 24h, T= 20 C Patent; KOPRAN RESEARCH LABORATORIES LTD; WO2007/29266; (2007); (A2) English View in Reaxys 76.7 % Example Name 1; 2 100g (0. 136G moles) of azaerythromycin A was dissolved in 300ML of acetone under stirring at room temperature. Formic acid (85percent, 15.6g, 0. 288G moles) and formaldehyde solution (37percent, 14. 10G, 0. 1737G moles) were added and resulting mixture was heated at 50- 55C for 8 hrs. The mixture was then cooled to room temperature and stirred with 16ML of 30percent aqueous NAOH solution. The aqueous layer was separated and acetone layer containing material was filtered through polishing filter and the clear filtrate was heated to 38 to 40C. The first portion of water (70ML) was added to this in about 1 hr maintaining a temperature of 38 to 40C followed by stirring for 2hrs at the same temperature to allow abundant formation of crystals. The second portion of water (380ML) was then added in about 2 hrs and thereafter maintained for 8-10 hrs at 38-40C. The resulting crystals were cooled to 10 to 15C, maintained for 2hrs and recovered by filtration. The crystals were washed with 50ML X 2 of chilled water and dried under vacuum at 45 to 50C till constant weight furnishing 80gms of azithromycin dihydrate in 80percent w/w yield from azaerythromycin A (74.9percent of theoretical) with a moisture content of 4. 7percent. EXAMPLE 2 Example 1 was repeated except that the second portion of water used in the CRYSTALLIZATION PROCESS CONTAINED LOML OF LIQ. ammonia (i. e. 370MLOFWATER+ 10MLOFLIQ. ammonia). Thus, 82g of azithromycin dihydrate was obtained in 82percent w/w yield from azaerythromycin A (76.7percent of theoretical). Stage 1: With formic acid in water, acetone, Time= 8h, T= 20 - 55 C Stage 2: With water in acetone, Time= 10 - 12h, T= 38 - 40 C Stage 3: With water Patent; JUBILANT ORGANOSYS LIMITED; WO2005/3144; (2005); (A1) English View in Reaxys 73 - 74.9 % Example Name 3; 4; 5; 6 EXAMPLE 3 100g (0.136g moles) of azaerythromycin A was dissolved in 400mL of chloroform under stirring at room temperature. Formic acid (85percent, 15.6g, 0. 288G. moles) and formaldehyde solution (37percent, 14. 10G, 0. 1737G
4/55
2011-04-19 08:56:52
moles) were added and the resulting mixture was heated at 50-55C for 10HRS. The mixture was then cooled to room temperature and washed with 25ML X 2 of 10percent aq. NAOH solution. The chloroform layer was separated, dried over anhydrous magnesium sulphate and distilled off completely under reduced pressure till dryness. This was further chased with 100mL of acetone till dryness. The residual product was cooled to room temperature and dissolved in 300ML of acetone and the resulting solution was filtered through polishing filter and crystallization was carried out as per the procedure given in Example 1 to get 78g of azithromycin dihydrate in 78percent. w/w from azaerythromycin A (73percent of theoretical). EXAMPLE 4 The procedure described in Example 3 was repeated but using methylene dichloride as a solvent during the reaction (20 hrs/reflux conditions) to furnish 80g of azithromycin dihydrate in 80percent w/w yield from azaerythromycin A (74.9percent of theoretical). EXAMPLE 5 100g (0. 136G moles) of azaerythromycin A was dissolved in 400mL of chloroform under stirring at room temperature. Formic acid (85percent, 15.6g, 0.288g. moles) and formaldehyde solution (37percent, 14. 10G, 0. 1737G moles) were added and the resulting mixture was heated at 50-55C for 10hrs. The mixture was then cooled to room temperature and washed with 25mL X 2 of 10percent aq. NAOH solution. The chloroform layer was separated. Mixture of Hydrochloric acid and water (20ML Con HC1 + 380ML water) added to the chloroform layer, stir for 15 minutes and separate the aqueous layer. The aqueous layer was washed with 200 ml chloroform. The aqueous layer cool to 25-30C and adjust the aqueous layer pH to 9. 5-10.00 by using 30percent aqueous NAOH solution. The resulting solid was extracted with chloroform. The chloroform layer was washed with 100 ml water. Chloroform layer dried over anhydrous magnesium sulphate and distilled off completely under reduced pressure till dryness. This was further chased with 100mL of acetone till dryness. The residual product was cooled to room temperature and dissolved in 300mL of acetone and the resulting solution was filtered through polishing filter and crystallization was carried out as per the procedure given in Example 1 to get 78g of azithromycin dihydrate in 78percent w/w from azaerythromycin A (73percent of theoretical). EXAMPLE 6 The procedure described in Example 5 was repeated but using methylene dichloride as a solvent during the reaction (20 hrs/reflux conditions) to furnish 80g of azithromycin dihydrate in 80percent w/w yield from azaerythromycin A (74.9percent of theoretical). SCHEME H H HO OH H3 H3 Ho OH CH3 CH3 0 0 H3C"\\CH3 H3C OCH3 'cl CH3 + H (|) H3 9-deoxo-9a-aza-9ahomoerythromycin (azaerythromycin A) Step-1 Formic acid I Formaldehyde CH \\ 3 \\\\cl 3 \\ OH OH v H3C/. H3c",//0 OCH3 1 CH3 wCH3 \\o OH Single () ) Step (Current Hygroscopic azithromycin monohydrate (= Azithromycin Crude) invention) Step-2 Crystallization cl HgC-\\CH \\ W 3C/t CH3 C ? XCH3 OH QH 3 H3c,/, \\, \\CH 3 OH , g3 C/ss, u I I O H3 CH3 H CH3 CH3 H Ici 3 Non-hygroscopic azithromycin dihydrate Stage 1: With formic acid in chloroform, water, Time= 10 - 20h, T= 20 - 55 C , Heating / reflux Stage 2: With water in acetone, Time= 10 - 12h, T= 38 - 40 C Patent; JUBILANT ORGANOSYS LIMITED; WO2005/3144; (2005); (A1) English View in Reaxys
HN HO
O OH
OH O O
OH N
N O HO HO HO O N OH
O
H
HO O O O OH O O
O O O
O OH
Rx-ID: 22962486 View in Reaxys Yield 95 % Conditions & References Example Name 2 Example Title EXAMPLE 2; Preparation of crystalline azithromycin monohydrate 100 [G] of crystalline 9a-deoxo-9a-aza-9a-homoerythromycin A obtained as described in the preceding example, 9.2 [G] of [PARAFORMALDEHYDE,] 44.9 ml of triethylamine and 603 ml of isopropyl acetate are fed into a 2 litre reactor equipped with a mechanical stirrer, condenser and thermometer. The mixture is then brought to [50.deg.C] and 12.2 [ML] of formic acid are added. The heterogeneous mixture is heated to [70.deg.C] and maintained under these conditions for 4 hours, at the end of which it is cooled to ambient temperature and 320 [ML] of de-ionised water are added to the mixture, which is treated with 12.8 ml of 30 sodium hydroxide. The phases are separated and the aqueous phase is again extracted with 192 ml of isopropyl acetate. The pooled organic extracts are then evaporated to dryness and redissolved in 225 mi of absolute ethanol. 675 ml of deionised water are slowly added to the solution obtained, which is brought to [50.deg.C,] observing the progressive turbidity of the mixture, which over time gives rise to a suspension of crystalline material. The mixture is maintained at [20-25.deg.C] for 4 hours, then filtered and washed with 130 ml of deionised water. The crystalline solid is discharged and dried at [40.deg.C] for 12 hours under a residual pressure of 40 mm Hg. The dry solid consisting of crystalline azithromycin weighs 96.1 g (yield 95percent). The spectroscopic data
5/55
2011-04-19 08:56:52
[(IR,] NMR, XRD) and the spectrum confirm that this is crystalline azithromycin monohydrate. TLC and HPLC analyses confirm that the azithromycin monohydrate obtained in this example presents a greater purity than the corresponding product in monohydrate form obtained as described in [USP4,] 474, 768. With triethylamine in isopropanol acetate, Time= 4h, T= 70 C , Eschweiler-Clarke Reaction Patent; Chemi SpA; WO2003/102009; (2003); (A1) English View in Reaxys
N N HO OH OH HO
N HO N OH
O
H HO
OH O
O O O O O OH
O 2 O O OH OH O O HO HO O HO O
OH O
O
OH O
Rx-ID: 25669685 View in Reaxys Yield 93 % Conditions & References Example Name 1.B Method B37.5g of azithromycin anhydrate (50mmol, moisture content 0.2percent) was dissolved in 400ml of anhydrous 2-propanol, and 13.4g of L-malic acid (lOOmmol) was added thereto, followed by stirring the resulting solution over night at room temperature, and then, for 2 hours at 0 to 5 C . The 0 precipitate formed was filtered, washed with cold 2-propanol, and dried at 45 C , to obtain 47.3 g of the title compound (yield: 93percent) as a white crystal.M.P.: 182-184 CSpecific rotation, [?]D20: -32.8 (c=l, methanol) 5 Moisture content (Karl-Fisher titrator): 0.4percent or less (after drying)IR (KBr, cm"1): 3415, 3057, 2980, 2932, 2884, 1736, 1607, 1462, 1386, 1326, 1177, 1084, 106O5 1000, 939, 895, 726, 637.The azithromycin L-malate compound obtained above was subjected 0 to X-ray diffraction analysis, and the result showed that it had a crystal structure having major peaks of 1/I0 values of at least 10percent at 20=1=0.2 of 6.0, 10.0, 11.0, 11.4, 12.5, 13.9, 15.5, 16.2, 17.3, 18.0, 19.2, 20.0, 20.5, 20.8, 21.2, 22.6, 24.5, 25.7. Its anhydrate form was confirmed by the result of moisture content measurement. 5 The azithromycin L-malate anhydrate thus obtained was exposed at40 C and 75percent relative humidity for 10 hours, and found that its moisture content is increased by about 2.0percent. That is, the azithromycin L-malate anhydrate was converted into a hydrate form thereof. in isopropyl alcohol, T= 0 - 20 C Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys 90 % Example Name 1 Example Title Preparation of Azithromycin L-Malate Monohydrate from L-Malic Acid 100.0 g of azithromycin dihydrate (127 mmol) was dissolved in 1,000 ml of 95percent 2-propanol, and 34.1 g. of L-malic acid (254 mmol) having an optical purity of 99.7percent ee was added thereto, followed by stirring the resulting solution overnight at room temperature and then for 2 hours at 0 to 5.deg. C. The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45.deg. C., to obtain 118.3 g of the title compound (yield: 90percent) as a white crystal.M.P.: 173175.deg. C.Specific rotation, []D 20: -32.8.deg. (c=1, methanol)Moisture content (Karl-Fisher titrator): 1.80percent (calculated for monohydrate, 1.74percent)Optical purity of malic acid after salt formation (HPLC): 99.9percent ee of L-malic acidAzithromycin relative content (HPLC): 74.6percent (calculated for one molecule, 72.35percent)Lmalic acid relative content (0.1N KOH titration): 25.8percent (calculated for two molecules, 25.91percent)IR (KBr, cm-1): 3411, 3059, 2971, 1742, 1716, 1619, 1594, 1493, 1457, 1345, 1286, 1177, 1112, 1080, 1056, 1013, 1001, 900, 773, 637The X-ray powder diffraction spectrum of the crystalline azithromycin L-malate monohydrate obtained (FIG. 1) show that the azithromycin L-malate monohydrate is a crystal having distinctively characteristic main peaks (those having I/I0 and d values of at least 10percent). in water, isopropyl alcohol, T= 0 - 20 C , Product distribution / selectivity Patent; Hanmi Pharm Co., Ltd; US2009/318375; (2009); (A1) English View in Reaxys
6/55
2011-04-19 08:56:52
OH N O O Si OH O O O O
O O O HO OH N N OH HO
N OH
O O O
O O O Si
OH
Rx-ID: 28629924 View in Reaxys Yield 89 % Conditions & References With tetrabutyl ammonium fluoride in tetrahydrofuran, Time= 5h, T= 20 C , Inert atmosphere Kim, Hyoung Cheul; Kang, Sung Ho; Angewandte Chemie, International Edition; vol. 48; nb. 10; (2009); p. 1827 1829 View in Reaxys
HO O O
OH
OH O O O O O OH OH N 2 H O H
HO O O
OH
OH O O O O O OH OH N H O H
Rx-ID: 23326915 View in Reaxys Yield Conditions & References Example Name 6 EXAMPLE 6 [00107] 70.0 g of azithromycin dihydrate are dissolved in 280 ml of methyl acetate at 25.deg.. The resulting solution is heated to 55-60.deg. and 225 ml of methyl acetate are distilled off. the distillation residue is cooled to 20.deg.. Azithromycin in the form of a monohydrate crystallizes, is filtrated off and dried. [00108] Yield: 47.5 g. Water content: 2.5percent in methyl acetate, T= 20 - 60 C Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys Example Name 7 EXAMPLE 7 [00109] 15.0 g of azithromycin dihydrate are dissolved in 75 ml of acetone, anhydrous sodium sulphate is added, the mixture obtained is stirred for ca. 10 minutes and the solid is filtrated off and washed with 15 ml of acetone. From the solution obtained 57 ml of acetone are distilled off and the resulting suspension is cooled to room temperature. Azithromycin in the form of a monohydrate crystallizes, is filtrated off and dried. [00110] Yield: 7.3 g. Water content: 2.6percent With sodium sulfate in acetone, Time= 0.166667h Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys Example Name 10 EXAMPLE 10 [00115] 20 g of azithromycin in the form of a dihydrate, suspended in 40 ml of water are treated with 2N HCl. A solution is obtained, is filtered and the filtrate is added dropwise to 80 ml of water keeping the pH between 10 and 11 by addition of 0.5 N sodium hydroxide at a temperature of ca. 55.deg.. The suspension obtained is cooled to room temperature and stirred for ca. 30 minutes. A solid precipitate obtained is filtrated off, washed with water and
7/55
2011-04-19 08:56:52
dried. 18.2 g of azithromycin in the form of a monohydrate are obtained. Water content: 3.7percent. Residual solvent: acetone 0.01percent. [00116] Azithromycin assay on anhydrous basis (HPLC): 98.6percent. Stage 1: With hydrogenchloride in water Stage 2: With sodium hydroxide in water, Time= 0.5h, T= 20 - 55 C , pH= 10 - 11 Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys Example Name 8 EXAMPLE 8 [00111] 10.0 g of azithromycin dihydrate are suspended in 10 ml of absolute ethanol and the mixture is heated. A clear solution is obtained, which is cooled slowly to room temperature and stirred at ca. 25.deg. for ca. one hour. Azithromycin in the form of a monohydrate crystallizes. Ethanol is evaporated off and azithromycin in the form of a monohydrate is filtrated off and dried. [00112] Yield: 5.26 g. Water content: 1.9percent in ethanol, Time= 1h, T= 20 C Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys
N
HO
HO O O
OH
O OH HO
O OH
N O 2 HO O O O O OH O OH HO HO O HO O OH O
Rx-ID: 25678888 View in Reaxys Yield 78 % Conditions & References Example Name 3 Reference Example 3: Preparation of azithromycin DL-malate anhydrate10.0g of azithromycin dihydrate (12.7mmol) was dissolved in 100mL of anhydrous 2-propanol, and 3.4 Ig of DL-malic acid (25.4mmol, an optical purity of 1.7percent ee in favor of L-malic acid) was added thereto, followed by stirring over night at room temperature, and then, for 2 hours at 0 to 5 C . The precipitate formed was filtered, washed with cold 2-propanol, and dried in a 40 C oven, to obtain 10.3 g of the title compound (yield: 78percent) as a white crystalline powder.M.P.: 169~172 CSpecific rotation, [?]D : -35.5 (c=l, methanol) Optical purity of malic acid (HPLC): 3.4percent ee of L-malic acid Moisture content (Karl-Fisher titrator): 0.5percent or less (after drying) IR (KBr, cm"1): 3410, 2973, 2937, 2882, 1736, 1603, 1458, 1385, 1170, 1076, 1060, 1016, 1008, 895, 641The azithromycin DL-malate compound obtained above was subjected to X-ray diffraction analysis, which showed a crystal structure having major peaks (1/I0 values of at least 10percent) at 2?+-0.2 of 5.9, 9.9, 10.9, 11.3, 12.4, 16.0, 17.2, 17.9, 19.9, 20.6, 22.5, 24.4. It was also shown to an anhydrate form by the measurement of moisture content. However, its moisture content is increased to 6percent or higher when exposed at 40 C and 75percent relative humidity for 10 hours.Meanwhile, instead of the azithromycin DL-malate anhydrate 0 obtained above, the non-hygroscopic azithromycin L-malate monohydrate was crystallized under the aqueous solvent condition, as shown in Example 8. in isopropyl alcohol, T= 0 - 20 C Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
8/55
2011-04-19 08:56:52
N
HO
HO O O
OH
OH O O O OH N 2 H O H
O H
OH
N O OH O
OH
OH
2 HO O
OH HO HO
HO O O O O O OH
O O OH
Rx-ID: 25681579 View in Reaxys Yield 79 % Conditions & References Example Name 2 Example 2: Preparation of azithromycin D-malate anhydrate 10.Og of azithromycin dihydrate (12.7mmol) was dissolved in 100mL of anhydrous 2-propanol, and 3.4 Ig of D-malic acid (25.4mmol) having an optical purity of 98.2percent ee was added thereto, followed by stirring over night at room temperature, and then, for 2 hours at 0 to 5 C . The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45 C5 to obtain 10.4 g of the title compound (yield: 79percent) as a white crystal.M.P.: 160-163 CSpecific rotation, [?]25: -39.5 (c=l, methanol) Optical purity of D-malic acid after salt formation (HPLC): 98.9percent ee Moisture content (Karl-Fisher titrator): 0.4percent or less (after drying) IR (KBr5 cm'1): 3427, 2974, 2937, 2882, 1735, 1598, 1466, 1385, 1179, 1171, 1080, 1060, 1013, 1002, 899, 726.The azithromycin D-malate compound obtained above was subjected to X-ray diffraction analysis, and the result showed that it had a crystal structure showing major peaks (1/I0 values of at least 10percent) at 2?+-0.2 of 5.7, 9.9, 10.9, 11.3, 12.3, 15.9, 17.1, 17.8, 18.2, 19.9, 20.6, 22.2. Its anhydrate form was confirmed by the result of moisture content measurement. However, it showed an increase of moisture content of 8percent or higher when exposed at 40 C and 75percent relative humidity for 10 hours.The azithromycin D-malate anhydrate obtained above did not convert to a hydrate form under the aqueous solvent condition employed in Examples 1 to 8. in isopropyl alcohol, T= 0 - 20 C Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
N N HO
O HO OH O OH
N HO N O OH O 2 HO O O O O OH HO HO O HO O OH O
OH HO OH O O O O OH O O O
Rx-ID: 29012843 View in Reaxys Yield 78 % Conditions & References Example Name 3 Example Title Preparation of Azithromycin DL-Malate Anhydrate 10.0 g of azithromycin dihydrate (12.7 mmol) was dissolved in 100 ml of anhydrous 2-propanol, and 3.41 g of DL-malic acid (25.4 mmol, an optical purity of 1.7percent ee in favor of L-malic acid) was added thereto, followed by stirring over night at room temperature, and then, for 2 hours at 0 to 5.deg. C. The precipitate formed was filtered, washed with cold 2-propanol, and dried in a 40.deg. C. oven, to obtain 10.3 g of the title compound (yield: 78percent) as a white crystalline powder.M.P.: 169172.deg. C.Specific rotation, []D 25: -35.5.deg. (c=1, methanol)Optical purity of malic acid (HPLC): 3.4percent ee of L-malic acidMoisture content (Karl-Fisher titrator): 0.5percent or less (after drying)IR (KBr, cm-1): 3410, 2973, 2937, 2882, 1736, 1603, 1458, 1385, 1170, 1076, 1060, 1016, 1008, 895, 641The azithromycin DL-malate compound obtained above was subjected to X-ray diffraction analysis, which showed a crystal structure having major peaks (I/Io values of at least 10percent) at 2+/-0.2 of 5.9, 9.9, 10.9, 11.3, 12.4, 16.0, 17.2, 17.9, 19.9, 20.6, 22.5, 24.4. It was also shown to an anhydrate form by the measurement of moisture content. However, its moisture content is increased to 6percent or higher when exposed at 40.deg. C. and 75percent relative humidity for 10 hours. in isopropyl alcohol, T= 0 - 20 C
9/55
2011-04-19 08:56:52
Patent; Hanmi Pharm Co., Ltd; US2009/318375; (2009); (A1) English View in Reaxys
N N HO OH OH HO
N HO N O OH O 2 HO O O O
O OH
O H
OH OH OH
O O O O
OH HO HO
HO O O OH O
Rx-ID: 29012844 View in Reaxys Yield 79 % Conditions & References Example Name 2 Example Title Preparation of Azithromycin D-Malate Anhydrate 10.0 g of azithromycin dihydrate (12.7 mmol) was dissolved in 100 ml of anhydrous 2-propanol, and 3.41 g of D-malic acid (25.4 mmol) having an optical purity of 98.2percent ee was added thereto, followed by stirring over night at room temperature, and then, for 2 hours at 0 to 5.deg. C. The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45.deg. C., to obtain 10.4 g of the title compound (yield: 79percent) as a white crystal.M.P.: 160163.deg. C.Specific rotation, []D 25: -39.5.deg. (c=1, methanol)Optical purity of D-malic acid after salt formation (HPLC): 98.9percent eeMoisture content (Karl-Fisher titrator): 0.4percent or less (after drying)IR (KBr, cm-): 3427, 2974, 2937, 2882, 1735, 1598, 1466, 1385, 1179, 1171, 1080, 1060, 1013, 1002, 899, 726.The azithromycin D-malate compound obtained above was subjected to X-ray diffraction analysis, and the result showed that it had a crystal structure showing major peaks (I/Io values of at least 10percent) at 2+/-0.2 of 5.7, 9.9, 10.9, 11.3, 12.3, 15.9, 17.1, 17.8, 18.2, 19.9, 20.6, 22.2. Its anhydrate form was confirmed by the result of moisture content measurement. However, it showed an increase of moisture content of 8percent or higher when exposed at 40.deg. C. and 75percent relative humidity for 10 hours. in isopropyl alcohol, T= 0 - 20 C Patent; Hanmi Pharm Co., Ltd; US2009/318375; (2009); (A1) English View in Reaxys
HN N HO OH O O O O OH O O O
O
OH HO
HO O O O O O OH OH OH O OH N H O H
Rx-ID: 25467806 View in Reaxys Yield Conditions & References Example Name 1 Example Title Hygroscopic Azithromycin Monohydrate PREPARATION 1 Hygroscopic Azithromycin Monohydrate Substantially following the methylation procedure of Kobrehel et al., U.S. Patent 4,517,359; and the crystallization procedure of Bright, U.S. Patent 4,474,768; 9-deoxo-9a-aza-9a-homoerythromycin A (previously called 11-aza-10deoxo-10-dihydroerythromycin A; 100 g, 0.218 mol) was dissolved with stirring in 400 ml CHCl3. Formic acid (98percent; 10.4 ml, 0.436 mol) and formaldehyde (37percent; 16.4 ml, 0.349 mol) were added over 4-5 minutes, and the mixture heated at reflux for 20 hours. The mixture was cooled to ambient temperature, diluted with 400 ml H2O and adjusted to pH 10.5 with 50percent NaOH. The aqueous layer was separated and extracted 2 x 100 ml with fresh CHCl3.
10/55
2011-04-19 08:56:52
The organic layers were combined, stripped in vacuo to 350 ml, twice diluted with 450 ml of ethanol and restripped to 350 ml, and finally diluted with 1000 ml H2O over a 1 hour period, pausing for 15 minutes as a slurry began to develop after the addition of about 250 ml of H2O. Title product was recovered by filtration and dried in air at 50.deg.C for 24 hours, 85 g; mp 136.deg.C; differential thermal analysis (heating rate 20.deg.C/minute) shows an endotherm at 142.deg.C; thermal gravimetric analysis (heating rate 30.deg.c/minute) shows a 2.6percent weight loss at 100.deg.C and a 4.5percent weight loss at 150.deg.C; water content 3.92percent; ethanol content 1.09percent. Anal. Calcd. for C3 8H7 2N2O1 2 (corrected for ethanol and water content): C, 58.46; H, 9.78; N, 3.74; Alkoxy, 4.67. Found: C, 58.40; H, 9.29; N, 3.50; Alkoxy, 4.52. With formaldehyd, formic acid in ethanol, chloroform, water Patent; PFIZER INC.; EP307128; (1989); (A2) English View in Reaxys Example Name 1 Example Title Hygroscopic Azithromycin Monohydrate PREPARATION 1 Hygroscopic Azithromycin Monohydrate Substantially following the methylation procedure of Kobrehel et al., U.S. Pat. No. 4,517,359; and the crystallization procedure of Bright, U.S. Pat. No. 4,474,768; 9-deoxo-9a-aza-9a-homoerythromycin A (previously called 11-aza-10-deoxo-10-dihydroerythromycin A; 100 g, 0.218 mol) was dissolved with stirring in 400 ml CHCl3. Formic acid (98percent; 10.4 ml, 0.436 mol) and formaldehyde (37percent; 16.4 ml, 0.349 mol) were added over 4-5 minutes, and the mixture heated at reflux for 20 hours. The mixture was cooled to ambient temperature, diluted with 400 ml H2O and adjusted to pH 10.5 with 50percent NaOH. The aqueous layer was separated and extracted 2*100 ml with fresh CHCl3. The organic layers were combined, stripped in vacuo to 350 ml, twice diluted with 450 ml of ethanol and restripped to 350 ml, and finally diluted with 1000 ml H2O over a 1 hour period, pausing for 15 minutes as a slurry began to develop after the addition of about 250 ml of H2O. Title product was recovered by filtration and dried in air at 50.deg. C. for 24 hours, 85 g; mp 136.deg. C.; differential thermal analysis (heating rate 20.deg. C./minute) shows an endotherm at 142.deg. C.; thermal gravimetric analysis (heating rate 30.deg. C./minute) shows a 2.6percent weight loss at 100.deg. C. and a 4.5percent weight loss at 150.deg. C.; water content 3.92percent; ethanol content 1.09percent. Anal. Calcd. for C38H72N2O12 (corrected for ethanol and water content): C, 58.46; H, 9.78; N, 3.74; Alkoxy, 4.67. Found: C, 58.40; H, 9.29; N, 3.50; Alkoxy, 4.52. With formaldehyd, formic acid in ethanol, chloroform, water Patent; Pfizer Inc.; US6268489; (2001); (B1) English View in Reaxys
N N HO OH OH HO
N N HO OH O O O O
O O OH
OH HO
O O O
O OH H 2O
Rx-ID: 23138429 View in Reaxys Yield Conditions & References Example Name 4.A Example Title Example 4; Preparation of the Orthorhombic Pseudopolymorph of Formula Id (S = cyclohexane); (Method A)
11/55
2011-04-19 08:56:52
Crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (5.0 g, having a water content of 5.7percent) was dissolved in 55 ml cyclohexane at a temperature of [70.deg.C.] The solution was treated with actived carbon, filtered, and cooled to room temperature over a period of 2 hours. The precipitated crystals were allowed to stand at room temperature for a further 15 hours. The crystals were isolated and dried at atmospheric pressure and room temperature to constant weight. The product was 4.7 g of the orthorhombic isostructural pseudopolymorph of Formula Id (S = cyclohexane). The water content was 2.35 percent, and the cyclohexane content was 7.9percent. Upon single x-ray diffraction analysis, the orthorhombic pseudopolymorph was characterized as identified in Table 1 and Figure 5. With water, T= 70 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys Example Name 8.D Example Title Example 8; Preparation of Orthorhombic Pseudopolymorph of the Formula Id (S = cyclohexane); (Method D) Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (5.0 g, having a water content of 3.8percent) was dissolved in 55 ml cyclohexane with stirring at a temperature of [40.deg.C.] n-hexane was gradually added stepwise at this temperature, with stirring until slight turbidity formed. The solution was then gradually cooled to room temperature over 5 hours and allowed to stand at this temperature, without stirring, for a further 18 hours. The resulting precipitate was a crystalline orthorhombic isostructural pseudopolymorph of the Formula Id (S = cyclohexane). The precipitate was filtered, washed with a minimum amount of cold 10percent v/v cyclohexane solution in n-hexane, and dried at atmospheric pressure and room temperature to constant weight. 4.9 g of the pseudopolymorph Id, analogous to that prepared in Example 4, was thus produced With water in hexane, T= 40 - 50 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys Example Name 7.C Example Title Example 7; Preparation of Orthorhombic Isostructural Pseudopolymorph of Formula Id (S = cyclohexane); (Method C) Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (5.0 g, having a water content of 3.8percent) was added to [55ML] cyclohexane. The mixture was heated to [40-50.deg.C] with stirring. The solution was treated with activated carbon, filtered, and cooled to a temperature of [15.deg.C] over a period of 2 hours. The mixture was seeded with the isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula Id (S = cyclohexane) and cooled stepwise to [0.deg.C] with stirring over a 24 hour period. The precipitate thus formed was the crystalline isostructural pseudopolymorph Id in the form of the cyclohexane solvate (S=cyclohexane). The precipitate was filtered, washed with a minimum amount of cold cyclohexane and dried to constant weight at atmospheric pressure and room temperature. 4.7 g of the pseudopolymorph Id, analogous to that prepared in Example 4 was thus produced. With water, T= 40 - 50 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
N N HO OH OH HO
N N HO OH O O O O O
O O OH
OH HO
O H
O
O
O O
O OH H 2O
Rx-ID: 23144538 View in Reaxys Yield Conditions & References Example Name 3.A
12/55
2011-04-19 08:56:52
Example Title Example 3; Preparation of the Orthorhombic Pseudopolymorph of Formula Ic (S= Methyl tert-butyl ether); (Method A) Crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (10.0 g, having a water content of 5.7percent) was dissolved in 45 ml methyl tert-butyl ether (MTBE) at a temperature of [50.deg.C.] The solution was treated with actived carbon, filtered, and cooled to room temperature over a period of 2 hours. The precipitated crystals were allowed to stand at room temperature for a further 15 hours. The crystals were isolated and dried at atmospheric pressure and room temperature to constant weight. The product was 8.8g of the orthorhombic isostructural pseudopolymorph of general Formula Ic (S = methyl tert-butyl ether). The water content was 2.4percent, and the MTBE content was 7.9percent. Upon single x-ray diffraction analysis, the orthorhombic pseudopolymorph was characterized as identified in Table 1 and Figure 4. With water, T= 50 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys Example Name 9.D Example Title Example 9; Preparation of Pseudopolymorph of Formula Ic (S = methyl tert-butanol ether); (Method D) 9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate (5.0 g, purity: USP 25) was dissolved in 54 ml methyl tert-butyl ether. The stirred solution was heated to [30-40.deg.C,] and subsequently added gradually over a period of 2 hours to 70 ml hexane at [40.deg.C,] under seeding with 250 mg of the orthorhombic isostructural pseudopolymorph of the general Formula Ic (S = methyl tert-butyl ether). The mixture was then gradually cooled to-10.deg.C over 24 hours. The thus precipitated crystalline orthorhombic isostructural pseudopolymorph of the general formula Ic (S = methyl tert-butyl ether) was filtered, washed with a minimum amount of cold methyl tert-butyl ether, and dried at atmospheric pressure and room temperature to constant weight. 7.8 g of the pseudopolymorph Ic, analogous to that prepared in Example 3, was thus obtained. With water in hexane, Time= 2h, T= 30 - 40 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
N N HO OH O O O O O O H O
O O
N N HO OH OH HO
OH HO
O O O
O OH H 2O
OH
Rx-ID: 23163719 View in Reaxys Yield 100 % Conditions & References Example Name 11 Example Title Example 11 The orthorhombic pseudopolymorph of the general Formula Ic (S = methyl tert- butyl ether) obtained according to Example 3, was dried at a temperature of [80.deg.C,] under a reduced pressure of 2 kPa to constant weight. The yield of the stable amorphous 9-deoxo-9a- aza-9a-methyl-9a-homoerythromycin A thus obtained was quantitative; purity: according to USP 25. A powder diffractogram and scanning electron microscopy (SEM) image of the stable amorphous product thus obtained are set forth in Figures 6 and 7, respectively. , T= 80 C , p= 15.0015Torr Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
13/55
2011-04-19 08:56:52
N HO HO N OH O 2 O O OH OH O O O H 2O HO HO O HO O OH O O 2 O OH OH O N OH O HO O HO O HO O
OH O
Rx-ID: 25686323 View in Reaxys Yield 85 % Conditions & References Example Name 7 Example 7: Preparation of azithromycin L-malate monohvdrate from azithromycin L-malate anhydrateo 50.Og of azithromycin L-malate anhydrate (moisture content 0.4percent) was dissolved in 400 ml of 95percent 2-propanol by warming, and the resulting solution was stirred overnight at room temperature and then for 2 hours at 0 to 5 C . The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45 C, to obtain 43.1 g of the title compound (yield: 85percent) as a 5 white crystal.M.P.: 173-175 CMoisture content (Karl-Fisher titrator): 1.83percent (calculated for monohydrate, 1.74percent) o The XPRD and IR absorption spectrum results of the compounds obtained were the same as those of Example 1. With water in isopropyl alcohol, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
N N HO OH HO OH O O O O
N N HO OH O O O O
O O OH
OH HO
O O H
O
O
O OH H 2O
Rx-ID: 23140180 View in Reaxys Yield Conditions & References Example Name 1.A Example Title Preparation of the Orthorhombic [PSEUDOPOLYMORPHS]; Example 1; Preparation of the Orthorhombic Pseudopolymorph of Formula la (S=1, 4-dioxane); (Method A) Crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (10.0 g, having a water content of 5.7percent) was dissolved in 20 ml dioxane at a temperature of [80.deg.C.] The solution was treated with actived carbon, filtered, and cooled to room temperature over a period of 3 hours. The precipitated crystals were allowed to stand at room temperature for another 15 hours. The crystals were isolated and dried at atmospheric pressure and room temperature to constant weight. The product was 3.8g of a crystalline orthorhombic isostructural pseudopolymorph of Formula la in the form of a 1,4-dioxane solvate (S = 1,4-dioxane). The water content (determined by KF titration), was 2.54percent and the 1,4dioxane content (determined by GC) was 10.5percent. Upon single crystal X-ray diffraction analysis, the orthorhombic pseudopolymorph was characterized as identified in Table 1 and Figure 2. With water, T= 80 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys Example Name 10.E Example Title Example 10; Preparation of Orthorhombic Pseudopolymorph of Formula Ia (S [= 1,] 4 dioxane) from a Native Solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A; (Method E) 60 ml of a native solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in ethyl acetate, prepared as described in WO 01/00640, was diluted with a further 40 ml of ethyl acetate. The resulting mixture was alkalized with 10percent
14/55
2011-04-19 08:56:52
[NAOH] solution to a pH value of 9.8, and the layers separated. The ethyl acetate layer was washed with a saturated sodium chloride solution, and treated with activated carbon. The mixture was filtered and the carbon remaining on the filter was washed with 5 [ML] ethyl acetate. To the combined ethyl acetate solution (both the filtrate and wash) 10 ml 1,4-dioxane was added. The ethyl acetate was distilled out at atmospheric pressure. The residue after distillation was slowly cooled from [100.deg.C] to [30.deg.C] over a period of 5 hours. The resulting precipitate was a crystalline isostructural pseudopolymorph of the general Formula la (S = 1,4-dioxane). The precipitate was filtered, washed with a minimum amount of cold aqueous 1,4-dioxane solution (10percent v/v) and dried at atmospheric pressure and room temperature to constant weight. 1.9 g of the pseudopolymorph [IA,] analogous to that prepared in Example 1, was obtained. Stage 1: With sodium hydroxide, water in ethyl acetate, pH= 9.8 Stage 2: in ethyl acetate Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
HN N HO OH
H O H
OH HO
HO OH O O O O O OH O OH N H O H
O O O O
O OH
O OH
Rx-ID: 24882375 View in Reaxys Yield Conditions & References Example Name 1 Example Title Hygroscopic Azithromycin Monohydrate PREPARATION 1 Hygroscopic Azithromycin Monohydrate Substantially following the methylation procedure of Kobrehel et al., U.S. Pat. No. 4,517,359; and the crystallization procedure of Bright, U.S. Pat. No. 4,474,768; 9-deoxo-9a-aza-9a-homoerythromycin A (previously called 11-aza-10-deoxo-10-dihydroerythromycin A; 100 g, 0.218 mol) was dissolved with stirring in 400 ml CHCl3. Formic acid (98percent; 10.4 ml, 0.436 mol) and formaldehyde (37percent; 16.4 ml, 0.349 mol) were added over 4-5 minutes, and the mixture heated at reflux for 20 hours. The mixture was cooled to ambient temperature, diluted with 400 ml H2 O and adjusted to pH 10.5 with 50percent NaOH. The aqueous layer was separated and extracted 2*100 ml with fresh CHCl3. The organic layers were combined, stripped in vacuo to 350 ml, twice diluted with 450 ml of ethanol and restripped to 350 ml, and finally diluted with 1000 ml H2 O over a 1 hour period, pausing for 15 minutes as a slurry began to develop after the addition of about 250 ml of H2 O. Title product was recovered by filtration and dried in air at 50.deg. C. for 24 hours, 85 g; mp 136.deg. C.; differential thermal analysis (heating rate 20.deg. C./minute) shows an endotherm at 142.deg. C.; thermal gravimetric analysis (heating rate 30.deg. C./minute) shows a 2.6percent weight loss at 100.deg. C. and a 4.5percent weight loss at 150.deg. C.; water content 3.92percent; ethanol content 1.09percent. Anal. Calcd. for C38 H72 N2 O12 (corrected for ethanol and water content): C, 58.46; H, 9.78; N, 3.74; Alkoxy, 4.67. Found: C, 58.40; H, 9.29; N, 3.50; Alkoxy, 4.52. With formaldehyd, formic acid in ethanol, chloroform Patent; Pfizer Inc.; US4963531; (1990); (A1) English View in Reaxys
15/55
2011-04-19 08:56:52
N N HO OH OH HO
N HO N OH O
O O O O OH O
H HO
OH O
O
2 O OH OH
HO O HO
HO O O O O O OH
OH O
O
H 2O
Rx-ID: 25669684 View in Reaxys Yield 87 % Conditions & References Example Name 2 Examples 2 to 6: Preparation of azithromycin L-malate monohydrate from L-malic acidThe procedure of Example 1 was repeated except that azithromycin, L-malic acid and the solvent as shown in Table 3 were used, to obtain the title compound. Table 3 With water in isopropyl alcohol, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
H O H
N O HO HO HO O N OH
N O HO HO HO O N OH
O O O
O O
O OH
O OH
Rx-ID: 4853368 View in Reaxys Yield 84.2 % Conditions & References With water in acetone, Time= 24h, Ambient temperature Bayod-Jasanada, Miguel; Carbajo, Rodrigo J.; Lopez-Ortiz, Fernando; Journal of Organic Chemistry; vol. 62; nb. 21; (1997); p. 7479 - 7481 View in Reaxys
N O HO
(v3)
N
OH
O HO HO O
N
OH N
O O
HO O
HO
O O O
O O
O
O OH
OH
Rx-ID: 4850012 View in Reaxys Yield 70.5 % Conditions & References With sulfuric acid in water, acetonitrile, Time= 0.5h, T= 15 C , pH 2 Bayod-Jasanada, Miguel; Carbajo, Rodrigo J.; Lopez-Ortiz, Fernando; Journal of Organic Chemistry; vol. 62; nb. 21; (1997); p. 7479 - 7481 View in Reaxys
16/55
2011-04-19 08:56:52
N HO OH
O HO OH HO HO OH O O O N
HO OH O H O
HO HO O O O
OH
HO OH
O O
O OH
HO O
OH
O O O
O H
O O
OH
Rx-ID: 23234068 View in Reaxys Yield Conditions & References Example Name 1 Example Title Example 1. Preparation of azithromycin hydrogen citrate 20g of azithromycin are added to 100ML of acetone (water content according to Karl-Fisher of 1 to 5percent), the mixture is stirred at ambient temperature until dissolved. 5.35g of citric acid are added and the mixture is heated at reflux. It is then cooled to 0-5.deg.C, filtered, washed with acetone and dried under vacuum at 40.deg.C to yield 22.4g of azithromycin hydrogen citrate (water content according to Karl-Fisher of 1. 2percent and acetone content less than 0.5percent). The azithromycin content determined by HPLC is 80percent and the citric acid content by electrometric titration is 20percent, corresponding to the stoichiometric ratio of the azithromycin hydrogen citrate. The salt can contain up to 8percent water depending on the drying method (by vacuum, fluidised bed, static), but is preferably 6percent, under relative humidity conditions of 40percent. Figures 1,2 and 3 show the X-ray diffraction spectrum, the carbon 13 nuclear magnetic resonance spectrum (13C-NMR) in solid state and the IR spectrum, recorded on KBr tablet, respectively. in acetone, Heating / reflux Patent; QUIMICA SINTETICA, S.A.; WO2004/106355; (2004); (A1) English View in Reaxys Example Name 2 Example Title Example 2. Preparation of azithromycin hydrogen citrate 20g of azithromycin dihydrate and 3.5g of citric acid monohydrate are added to 50 ml of methyl acetate. This is heated at reflux, cooled to ambient temperature, filtered, washed with methyl acetate and dried under vacuum at 40.deg.C. Figures 4,5, and 6 show the X-ray diffraction spectrum, the carbon 13 nuclear magnetic resonance spectrum (13CNMR) in solid state and the IR spectrum, recorded on KBr tablet, respectively. in methyl acetate, Heating / reflux Patent; QUIMICA SINTETICA, S.A.; WO2004/106355; (2004); (A1) English View in Reaxys Example Name 3 Example Title Example 3. Preparation of azithromycin hydrogen citrate Following the procedure set out in example 2 and replacing the methyl acetate by tetrahydrofuran, azithromycin hydrogen citrate is obtained. Figures 7,8 and 9 show the X-ray diffraction spectrum, the carbon 13 nuclear magnetic resonance spectrum (13C-NMR) in solid state and the IR spectrum, recorded on KBr tablet, respectively. in tetrahydrofuran, Heating / reflux Patent; QUIMICA SINTETICA, S.A.; WO2004/106355; (2004); (A1) English View in Reaxys
17/55
2011-04-19 08:56:52
H 1.5 O H N HO HO O O O O OH OH O O N
HO O O
OH
O OH
Rx-ID: 23333620 View in Reaxys Yield Conditions & References 57 - 100 % Example Name 2 To evaluate a proposed excipient, the active dose of the azithromycin was suspended with the desired amount of potential excipient in a 0.1 M phosphate buffer system adjusted to a pH of 8.16. The buffer system was created by dissolving 13.738 g of NaH2PO4*H2O in 900 ml of water, adjusting the pH to 8.16 with sodium hydroxide, and diluting the solution to 1 liter with water. The sample, once constituted with buffer, was then stored at room temperature for the desired constituted product shelf-life. The azithromycin product was then isolated through filtration, and the resulting solid filtrate analyzed by a Solid-State Nuclear Magnetic Resonance method described previously that allows for quantitation of the dihydrate form present. The effect of various individual flavoring components and of sucrose upon conversion of azithromycin form G to azithromycin dihydrate (form A), in suspensions, were evaluated as follows. An 820 mg dose of form G azithromycin was weighed and mixed with 200 mg of each flavoring or sucrose. The mass of each flavoring, used in this test, was chosen to match that of the anticipated required amount for effective flavoring in the constituted POS. In this example, five flavorings, specifically artificial creme de vanilla, BC banana, Trusil banana, Trusil cherry and artificial grape were investigated in addition to sucrose. Each of the binary samples were then constituted with 18 mls of pH=8.16 buffer and stored for 1, 5 and 10-days at room temperature. A control suspension of azithromycin form G constituted with 18 mls of pH=8.16 buffer was run with each series of experiments using the same storage conditions. Upon completion of the constituted storage time period these samples were filtered to isolate drug product and analyzed using the SS-NMR method to quantify the amount of azithromycin dihydrate present. The results of these studies are provided in the following Table 3. [Table 3.] Effect of Flavorings and Sucrose On Conversion of Azithromycin Form G to Form A) FormulationsConstituted 1 day ( percentForm A)Constituted 5 days ( percentForm A)Constituted 10 days ( percentForm A)Artificial Creme de Vanilla Flavor0percent4percent30percentBC Banana Flavor0percent27percentACTrusil Banana Flavor32percent57percentACSucrose2percent1percent6percentTrusil Cherry Flavor32percent75percentACArtificial Grape Flavor57percent75percentAC AC means all converted to form A As shown previously in Example 1, azithromycin form G, in combination with only water, experienced significant conversion to form A over the 10-day constitution interval. Further, when combined with a flavoring, such as Artificial Creme de vanilla, artificial grape, Trusil cherry, BC banana or Trusil banana, the rate of conversion substantially increased. Thus, this test shows that these five flavorings need to be stabilized for use in oral suspension formulations of azithromycin form G with a 5-10 day constituted shelf-life. However, suspensions with Artificial Creme de vanilla and BC banana flavorings did not exhibit conversion to azithromycin dihydrate (form A) during the first day after constitution. Further, the presence of sucrose, without flavoring, appears to have stabilized the azithromycin form G in a constituted suspension such that only minimal conversion to form A was observed over the 10-day period. This example demonstrated a simple method for choosing suitable excipients for non-dihydrate azithromycin oral suspensions that will minimize form conversion. With Artifical Grape Flavour, water, Time= 24 - 240h, T= 20 C , pH= 8.16, Aqueous phosphate buffer, Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 32 - 100 % Example Name 2 To evaluate a proposed excipient, the active dose of the azithromycin was suspended with the desired amount of potential excipient in a 0.1 M phosphate buffer system adjusted to a pH of 8.16. The buffer system was created by dissolving 13.738 g of NaH2PO4*H2O in 900 ml of water, adjusting the pH to 8.16 with sodium hydroxide, and diluting the solution to 1 liter with water. The sample, once constituted with buffer, was then stored at room temperature for the desired constituted product shelf-life. The azithromycin product was then isolated through filtration, and the resulting solid filtrate analyzed by a Solid-State Nuclear Magnetic Resonance method described previously that allows for quantitation of the dihydrate form present. The effect of various individual flavoring components and of sucrose upon conversion of azithromycin form G to azithromycin dihydrate (form A), in suspensions, were evaluated as follows. An 820 mg dose of form G azithromycin was weighed and mixed with 200 mg of each flavoring or sucrose. The mass of each
18/55
2011-04-19 08:56:52
flavoring, used in this test, was chosen to match that of the anticipated required amount for effective flavoring in the constituted POS. In this example, five flavorings, specifically artificial creme de vanilla, BC banana, Trusil banana, Trusil cherry and artificial grape were investigated in addition to sucrose. Each of the binary samples were then constituted with 18 mls of pH=8.16 buffer and stored for 1, 5 and 10-days at room temperature. A control suspension of azithromycin form G constituted with 18 mls of pH=8.16 buffer was run with each series of experiments using the same storage conditions. Upon completion of the constituted storage time period these samples were filtered to isolate drug product and analyzed using the SS-NMR method to quantify the amount of azithromycin dihydrate present. The results of these studies are provided in the following Table 3. [Table 3.] Effect of Flavorings and Sucrose On Conversion of Azithromycin Form G to Form A) FormulationsConstituted 1 day ( percentForm A)Constituted 5 days ( percentForm A)Constituted 10 days ( percentForm A)Artificial Creme de Vanilla Flavor0percent4percent30percentBC Banana Flavor0percent27percentACTrusil Banana Flavor32percent57percentACSucrose2percent1percent6percentTrusil Cherry Flavor32percent75percentACArtificial Grape Flavor57percent75percentAC AC means all converted to form A As shown previously in Example 1, azithromycin form G, in combination with only water, experienced significant conversion to form A over the 10-day constitution interval. Further, when combined with a flavoring, such as Artificial Creme de vanilla, artificial grape, Trusil cherry, BC banana or Trusil banana, the rate of conversion substantially increased. Thus, this test shows that these five flavorings need to be stabilized for use in oral suspension formulations of azithromycin form G with a 5-10 day constituted shelf-life. However, suspensions with Artificial Creme de vanilla and BC banana flavorings did not exhibit conversion to azithromycin dihydrate (form A) during the first day after constitution. Further, the presence of sucrose, without flavoring, appears to have stabilized the azithromycin form G in a constituted suspension such that only minimal conversion to form A was observed over the 10-day period. This example demonstrated a simple method for choosing suitable excipients for non-dihydrate azithromycin oral suspensions that will minimize form conversion. With Trusil Banana Flavour, water, Time= 24 - 240h, T= 20 C , pH= 8.16, Aqueous phosphate buffer, Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 32 - 100 % Example Name 2 To evaluate a proposed excipient, the active dose of the azithromycin was suspended with the desired amount of potential excipient in a 0.1 M phosphate buffer system adjusted to a pH of 8.16. The buffer system was created by dissolving 13.738 g of NaH2PO4*H2O in 900 ml of water, adjusting the pH to 8.16 with sodium hydroxide, and diluting the solution to 1 liter with water. The sample, once constituted with buffer, was then stored at room temperature for the desired constituted product shelf-life. The azithromycin product was then isolated through filtration, and the resulting solid filtrate analyzed by a Solid-State Nuclear Magnetic Resonance method described previously that allows for quantitation of the dihydrate form present. The effect of various individual flavoring components and of sucrose upon conversion of azithromycin form G to azithromycin dihydrate (form A), in suspensions, were evaluated as follows. An 820 mg dose of form G azithromycin was weighed and mixed with 200 mg of each flavoring or sucrose. The mass of each flavoring, used in this test, was chosen to match that of the anticipated required amount for effective flavoring in the constituted POS. In this example, five flavorings, specifically artificial creme de vanilla, BC banana, Trusil banana, Trusil cherry and artificial grape were investigated in addition to sucrose. Each of the binary samples were then constituted with 18 mls of pH=8.16 buffer and stored for 1, 5 and 10-days at room temperature. A control suspension of azithromycin form G constituted with 18 mls of pH=8.16 buffer was run with each series of experiments using the same storage conditions. Upon completion of the constituted storage time period these samples were filtered to isolate drug product and analyzed using the SS-NMR method to quantify the amount of azithromycin dihydrate present. The results of these studies are provided in the following Table 3. [Table 3.] Effect of Flavorings and Sucrose On Conversion of Azithromycin Form G to Form A) FormulationsConstituted 1 day ( percentForm A)Constituted 5 days ( percentForm A)Constituted 10 days ( percentForm A)Artificial Creme de Vanilla Flavor0percent4percent30percentBC Banana Flavor0percent27percentACTrusil Banana Flavor32percent57percentACSucrose2percent1percent6percentTrusil Cherry Flavor32percent75percentACArtificial Grape Flavor57percent75percentAC AC means all converted to form A As shown previously in Example 1, azithromycin form G, in combination with only water, experienced significant conversion to form A over the 10-day constitution interval. Further, when combined with a flavoring, such as Artificial Creme de vanilla, artificial grape, Trusil cherry, BC banana or Trusil banana, the rate of conversion substantially increased. Thus, this test shows that these five flavorings need to be stabilized for use in oral suspension formulations of azithromycin form G with a 5-10 day constituted shelf-life. However, suspensions with Artificial Creme de vanilla and BC banana flavorings did not exhibit conversion to azithromycin dihydrate (form A) during the first day after constitution. Further, the presence of sucrose, without flavoring, appears to have stabilized the azithromycin form G in a constituted suspension such that only minimal conversion to form A was observed over the 10-day period. This example demonstrated a simple method for choosing suitable excipients for non-dihydrate azithromycin oral suspensions that will minimize form conversion. With Trusil Cherry Flavour, water, Time= 24 - 240h, T= 20 C , pH= 8.16, Aqueous phosphate buffer, Conversion of starting material
19/55
2011-04-19 08:56:52
Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 13 % Example Name 3 The data showed that both the sucrose and vanilla flavorings contain only trace amounts of volatile organics that could result in the azithromycin form conversion. This correlated well to the lower conversion rate of these two formulation components. The Trusil cherry and banana flavorings, however, appeared to have significant amounts of volatile organics that may be responsible for the greater conversion enhancing behavior of these excipients. Standards of these identified solvent components were then used to investigate the source of the stability problem introduced by these flavorings. The estimated concentration of each solvent in a constituted POS was calculated based on the GC-MS quantification of the specified solvent in the flavorings. Aqueous solutions of each solvent/component were then created at these concentrations and 18 mls of each solvent-solution was used to constitute an unflavored POS formulation I sample using form G. The constituted drug suspensions were stored at room temperature for 24-hours, before being filtered and analyzed by SS-NMR for quantification of azithromycin form change over this interval. POS formulations I and II were constituted with 18 mls of water and stored identically to serve as controls for this experiment. The results of this investigation can be seen in Table 8, below. [Table 8.] Effects of Flavoring Components Upon Azithromycin Form G Conversion Form G POS FormulationConstitution Medium (18 mL)percentForm AFormulation IIWater71Formulation IWater0Formulation I0.197 mg/ml ethyl acetate0Formulation I0.002 mg/ml ethyl ester propanoic acid0Formulation I0.025 mg/ml 3-methyl-1-butanol0Formulation I0.815 mg/ml 3-methyl-butyl acetate2Formulation I0.144 mg/ml 2-methyl-butyl acetate0Formulation I0.587 mg/ml benzaldehyde0Formulation I0.043 mg/ml isoamyl isovalerate13Formulation I0.785 mg/ml 3-methyl-butyl acetate + 0.562 mg/ml benzaldehyde11 When constituted with water, form G azithromycin in POS formulation II demonstrated approximately 71percent conversion to azithromycin dihydrate. POS formulation I which is POS formulation II without the cherry, Trusil banana and vanilla flavorings, had no conversion to the azithromycin dihydrate when constituted with water. The constitution of POS formulation I with 3-methyl-butyl acetate and isoamyl isovalerate solutions, instead of water, exhibited an increased conversion to azithromycin dihydrate. As a result of this observation it is evident that an azithromycin POS formulation will be more stable if the levels of these organic components are minimized, or absent from the constituted POS all together. Flavorings should be chosen which do not contain these organic components for optimal POS stability. Furthermore, the stability of a constituted POS formulation can be improved by substituting flavorings that contain small amounts of these organic components for those in the formulation that have large amounts of these organic components. It was also demonstrated that these organic components may not enhance the conversion in an independent manner. Combinations of organic components, as demonstrated through constitution with a 0.785 mg/ml 3-methyl-butyl acetate and 0.562 mg/ml benzaldehyde solution, may also interact to further facilitate the formation of the dihydrate species as compared to the effect of individual isolated components. For this reason it is beneficial not only to avoid such combinations of components through careful flavoring choices, but also to choose flavorings with the least amount of organic components in order to minimize the probability of observing such a phenomenon. With iso-pentyl iso-pentanoate, water, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 11 % Example Name 3 The data showed that both the sucrose and vanilla flavorings contain only trace amounts of volatile organics that could result in the azithromycin form conversion. This correlated well to the lower conversion rate of these two formulation components. The Trusil cherry and banana flavorings, however, appeared to have significant amounts of volatile organics that may be responsible for the greater conversion enhancing behavior of these excipients. Standards of these identified solvent components were then used to investigate the source of the stability problem introduced by these flavorings. The estimated concentration of each solvent in a constituted POS was calculated based on the GC-MS quantification of the specified solvent in the flavorings. Aqueous solutions of each solvent/component were then created at these concentrations and 18 mls of each solvent-solution was used to constitute an unflavored POS formulation I sample using form G. The constituted drug suspensions were stored at room temperature for 24-hours, before being filtered and analyzed by SS-NMR for quantification of azithromycin form change over this interval. POS formulations I and II were constituted with 18 mls of water and stored identically to serve as controls for this experiment. The results of this investigation can be seen in Table 8, below. [Table 8.] Effects of Flavoring Components Upon Azithromycin Form G Conversion Form G POS FormulationConstitution Medium (18 mL)percentForm AFormulation IIWater71Formulation IWater0Formulation I0.197 mg/ml ethyl acetate0Formulation I0.002 mg/ml ethyl ester propanoic acid0Formulation I0.025 mg/ml 3-methyl-1-butanol0Formulation I0.815 mg/ml 3-methyl-butyl acetate2Formulation I0.144 mg/ml 2-methyl-butyl acetate0Formulation I0.587 mg/ml benzaldehyde0Formulation I0.043 mg/ml isoamyl isovalerate13Formulation I0.785 mg/ml 3-methyl-butyl acetate + 0.562 mg/ml benzaldehyde11 When constituted with water, form G azithromycin in POS formulation II demonstrated approximately 71percent conversion to azithromycin dihydrate. POS formulation I which is POS formulation II without the cherry, Trusil banana and vanilla flavorings, had no conversion to the azithromycin dihydrate when constituted with water. The constitution of POS formulation I with 3-methyl-butyl acetate and
20/55
2011-04-19 08:56:52
isoamyl isovalerate solutions, instead of water, exhibited an increased conversion to azithromycin dihydrate. As a result of this observation it is evident that an azithromycin POS formulation will be more stable if the levels of these organic components are minimized, or absent from the constituted POS all together. Flavorings should be chosen which do not contain these organic components for optimal POS stability. Furthermore, the stability of a constituted POS formulation can be improved by substituting flavorings that contain small amounts of these organic components for those in the formulation that have large amounts of these organic components. It was also demonstrated that these organic components may not enhance the conversion in an independent manner. Combinations of organic components, as demonstrated through constitution with a 0.785 mg/ml 3-methyl-butyl acetate and 0.562 mg/ml benzaldehyde solution, may also interact to further facilitate the formation of the dihydrate species as compared to the effect of individual isolated components. For this reason it is beneficial not only to avoid such combinations of components through careful flavoring choices, but also to choose flavorings with the least amount of organic components in order to minimize the probability of observing such a phenomenon. With iso-pentyl acetate, water, benzaldehyde, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 2% Example Name 3 The data showed that both the sucrose and vanilla flavorings contain only trace amounts of volatile organics that could result in the azithromycin form conversion. This correlated well to the lower conversion rate of these two formulation components. The Trusil cherry and banana flavorings, however, appeared to have significant amounts of volatile organics that may be responsible for the greater conversion enhancing behavior of these excipients. Standards of these identified solvent components were then used to investigate the source of the stability problem introduced by these flavorings. The estimated concentration of each solvent in a constituted POS was calculated based on the GC-MS quantification of the specified solvent in the flavorings. Aqueous solutions of each solvent/component were then created at these concentrations and 18 mls of each solvent-solution was used to constitute an unflavored POS formulation I sample using form G. The constituted drug suspensions were stored at room temperature for 24-hours, before being filtered and analyzed by SS-NMR for quantification of azithromycin form change over this interval. POS formulations I and II were constituted with 18 mls of water and stored identically to serve as controls for this experiment. The results of this investigation can be seen in Table 8, below. [Table 8.] Effects of Flavoring Components Upon Azithromycin Form G Conversion Form G POS FormulationConstitution Medium (18 mL)percentForm AFormulation IIWater71Formulation IWater0Formulation I0.197 mg/ml ethyl acetate0Formulation I0.002 mg/ml ethyl ester propanoic acid0Formulation I0.025 mg/ml 3-methyl-1-butanol0Formulation I0.815 mg/ml 3-methyl-butyl acetate2Formulation I0.144 mg/ml 2-methyl-butyl acetate0Formulation I0.587 mg/ml benzaldehyde0Formulation I0.043 mg/ml isoamyl isovalerate13Formulation I0.785 mg/ml 3-methyl-butyl acetate + 0.562 mg/ml benzaldehyde11 When constituted with water, form G azithromycin in POS formulation II demonstrated approximately 71percent conversion to azithromycin dihydrate. POS formulation I which is POS formulation II without the cherry, Trusil banana and vanilla flavorings, had no conversion to the azithromycin dihydrate when constituted with water. The constitution of POS formulation I with 3-methyl-butyl acetate and isoamyl isovalerate solutions, instead of water, exhibited an increased conversion to azithromycin dihydrate. As a result of this observation it is evident that an azithromycin POS formulation will be more stable if the levels of these organic components are minimized, or absent from the constituted POS all together. Flavorings should be chosen which do not contain these organic components for optimal POS stability. Furthermore, the stability of a constituted POS formulation can be improved by substituting flavorings that contain small amounts of these organic components for those in the formulation that have large amounts of these organic components. It was also demonstrated that these organic components may not enhance the conversion in an independent manner. Combinations of organic components, as demonstrated through constitution with a 0.785 mg/ml 3-methyl-butyl acetate and 0.562 mg/ml benzaldehyde solution, may also interact to further facilitate the formation of the dihydrate species as compared to the effect of individual isolated components. For this reason it is beneficial not only to avoid such combinations of components through careful flavoring choices, but also to choose flavorings with the least amount of organic components in order to minimize the probability of observing such a phenomenon. With iso-pentyl acetate, water, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 2-6% Example Name 2 To evaluate a proposed excipient, the active dose of the azithromycin was suspended with the desired amount of potential excipient in a 0.1 M phosphate buffer system adjusted to a pH of 8.16. The buffer system was created by dissolving 13.738 g of NaH2PO4*H2O in 900 ml of water, adjusting the pH to 8.16 with sodium hydroxide, and diluting the solution to 1 liter with water. The sample, once constituted with buffer, was then stored at room temperature for the desired constituted product shelf-life. The azithromycin product was then isolated through filtration, and the resulting
21/55
2011-04-19 08:56:52
solid filtrate analyzed by a Solid-State Nuclear Magnetic Resonance method described previously that allows for quantitation of the dihydrate form present. The effect of various individual flavoring components and of sucrose upon conversion of azithromycin form G to azithromycin dihydrate (form A), in suspensions, were evaluated as follows. An 820 mg dose of form G azithromycin was weighed and mixed with 200 mg of each flavoring or sucrose. The mass of each flavoring, used in this test, was chosen to match that of the anticipated required amount for effective flavoring in the constituted POS. In this example, five flavorings, specifically artificial creme de vanilla, BC banana, Trusil banana, Trusil cherry and artificial grape were investigated in addition to sucrose. Each of the binary samples were then constituted with 18 mls of pH=8.16 buffer and stored for 1, 5 and 10-days at room temperature. A control suspension of azithromycin form G constituted with 18 mls of pH=8.16 buffer was run with each series of experiments using the same storage conditions. Upon completion of the constituted storage time period these samples were filtered to isolate drug product and analyzed using the SS-NMR method to quantify the amount of azithromycin dihydrate present. The results of these studies are provided in the following Table 3. [Table 3.] Effect of Flavorings and Sucrose On Conversion of Azithromycin Form G to Form A) FormulationsConstituted 1 day ( percentForm A)Constituted 5 days ( percentForm A)Constituted 10 days ( percentForm A)Artificial Creme de Vanilla Flavor0percent4percent30percentBC Banana Flavor0percent27percentACTrusil Banana Flavor32percent57percentACSucrose2percent1percent6percentTrusil Cherry Flavor32percent75percentACArtificial Grape Flavor57percent75percentAC AC means all converted to form A As shown previously in Example 1, azithromycin form G, in combination with only water, experienced significant conversion to form A over the 10-day constitution interval. Further, when combined with a flavoring, such as Artificial Creme de vanilla, artificial grape, Trusil cherry, BC banana or Trusil banana, the rate of conversion substantially increased. Thus, this test shows that these five flavorings need to be stabilized for use in oral suspension formulations of azithromycin form G with a 5-10 day constituted shelf-life. However, suspensions with Artificial Creme de vanilla and BC banana flavorings did not exhibit conversion to azithromycin dihydrate (form A) during the first day after constitution. Further, the presence of sucrose, without flavoring, appears to have stabilized the azithromycin form G in a constituted suspension such that only minimal conversion to form A was observed over the 10-day period. This example demonstrated a simple method for choosing suitable excipients for non-dihydrate azithromycin oral suspensions that will minimize form conversion. With water, sugar powder, Time= 24 - 240h, T= 20 C , pH= 8.16, Aqueous phosphate buffer, Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 0 - 30 % Example Name 2 To evaluate a proposed excipient, the active dose of the azithromycin was suspended with the desired amount of potential excipient in a 0.1 M phosphate buffer system adjusted to a pH of 8.16. The buffer system was created by dissolving 13.738 g of NaH2PO4*H2O in 900 ml of water, adjusting the pH to 8.16 with sodium hydroxide, and diluting the solution to 1 liter with water. The sample, once constituted with buffer, was then stored at room temperature for the desired constituted product shelf-life. The azithromycin product was then isolated through filtration, and the resulting solid filtrate analyzed by a Solid-State Nuclear Magnetic Resonance method described previously that allows for quantitation of the dihydrate form present. The effect of various individual flavoring components and of sucrose upon conversion of azithromycin form G to azithromycin dihydrate (form A), in suspensions, were evaluated as follows. An 820 mg dose of form G azithromycin was weighed and mixed with 200 mg of each flavoring or sucrose. The mass of each flavoring, used in this test, was chosen to match that of the anticipated required amount for effective flavoring in the constituted POS. In this example, five flavorings, specifically artificial creme de vanilla, BC banana, Trusil banana, Trusil cherry and artificial grape were investigated in addition to sucrose. Each of the binary samples were then constituted with 18 mls of pH=8.16 buffer and stored for 1, 5 and 10-days at room temperature. A control suspension of azithromycin form G constituted with 18 mls of pH=8.16 buffer was run with each series of experiments using the same storage conditions. Upon completion of the constituted storage time period these samples were filtered to isolate drug product and analyzed using the SS-NMR method to quantify the amount of azithromycin dihydrate present. The results of these studies are provided in the following Table 3. [Table 3.] Effect of Flavorings and Sucrose On Conversion of Azithromycin Form G to Form A) FormulationsConstituted 1 day ( percentForm A)Constituted 5 days ( percentForm A)Constituted 10 days ( percentForm A)Artificial Creme de Vanilla Flavor0percent4percent30percentBC Banana Flavor0percent27percentACTrusil Banana Flavor32percent57percentACSucrose2percent1percent6percentTrusil Cherry Flavor32percent75percentACArtificial Grape Flavor57percent75percentAC AC means all converted to form A As shown previously in Example 1, azithromycin form G, in combination with only water, experienced significant conversion to form A over the 10-day constitution interval. Further, when combined with a flavoring, such as Artificial Creme de vanilla, artificial grape, Trusil cherry, BC banana or Trusil banana, the rate of conversion substantially increased. Thus, this test shows that these five flavorings need to be stabilized for use in oral suspension formulations of azithromycin form G with a 5-10 day constituted shelf-life. However, suspensions with Artificial Creme de vanilla and BC banana flavorings did not exhibit conversion to azithromycin dihydrate (form A) during the first day after constitution. Further, the presence of sucrose, without flavoring, appears to have stabilized the azithromycin form G in a constituted suspension such that
22/55
2011-04-19 08:56:52
only minimal conversion to form A was observed over the 10-day period. This example demonstrated a simple method for choosing suitable excipients for non-dihydrate azithromycin oral suspensions that will minimize form conversion. With Artifical Creme de Vanilla Flavour, water, Time= 24 - 240h, T= 20 C , pH= 8.16, Aqueous phosphate buffer, Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys 0 - 100 % Example Name 2 To evaluate a proposed excipient, the active dose of the azithromycin was suspended with the desired amount of potential excipient in a 0.1 M phosphate buffer system adjusted to a pH of 8.16. The buffer system was created by dissolving 13.738 g of NaH2PO4*H2O in 900 ml of water, adjusting the pH to 8.16 with sodium hydroxide, and diluting the solution to 1 liter with water. The sample, once constituted with buffer, was then stored at room temperature for the desired constituted product shelf-life. The azithromycin product was then isolated through filtration, and the resulting solid filtrate analyzed by a Solid-State Nuclear Magnetic Resonance method described previously that allows for quantitation of the dihydrate form present. The effect of various individual flavoring components and of sucrose upon conversion of azithromycin form G to azithromycin dihydrate (form A), in suspensions, were evaluated as follows. An 820 mg dose of form G azithromycin was weighed and mixed with 200 mg of each flavoring or sucrose. The mass of each flavoring, used in this test, was chosen to match that of the anticipated required amount for effective flavoring in the constituted POS. In this example, five flavorings, specifically artificial creme de vanilla, BC banana, Trusil banana, Trusil cherry and artificial grape were investigated in addition to sucrose. Each of the binary samples were then constituted with 18 mls of pH=8.16 buffer and stored for 1, 5 and 10-days at room temperature. A control suspension of azithromycin form G constituted with 18 mls of pH=8.16 buffer was run with each series of experiments using the same storage conditions. Upon completion of the constituted storage time period these samples were filtered to isolate drug product and analyzed using the SS-NMR method to quantify the amount of azithromycin dihydrate present. The results of these studies are provided in the following Table 3. [Table 3.] Effect of Flavorings and Sucrose On Conversion of Azithromycin Form G to Form A) FormulationsConstituted 1 day ( percentForm A)Constituted 5 days ( percentForm A)Constituted 10 days ( percentForm A)Artificial Creme de Vanilla Flavor0percent4percent30percentBC Banana Flavor0percent27percentACTrusil Banana Flavor32percent57percentACSucrose2percent1percent6percentTrusil Cherry Flavor32percent75percentACArtificial Grape Flavor57percent75percentAC AC means all converted to form A As shown previously in Example 1, azithromycin form G, in combination with only water, experienced significant conversion to form A over the 10-day constitution interval. Further, when combined with a flavoring, such as Artificial Creme de vanilla, artificial grape, Trusil cherry, BC banana or Trusil banana, the rate of conversion substantially increased. Thus, this test shows that these five flavorings need to be stabilized for use in oral suspension formulations of azithromycin form G with a 5-10 day constituted shelf-life. However, suspensions with Artificial Creme de vanilla and BC banana flavorings did not exhibit conversion to azithromycin dihydrate (form A) during the first day after constitution. Further, the presence of sucrose, without flavoring, appears to have stabilized the azithromycin form G in a constituted suspension such that only minimal conversion to form A was observed over the 10-day period. This example demonstrated a simple method for choosing suitable excipients for non-dihydrate azithromycin oral suspensions that will minimize form conversion. With BC Banana Flavour, water, Time= 24 - 240h, T= 20 C , pH= 8.16, Aqueous phosphate buffer, Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys
N
HO N
HO O O
OH
OH O O O O OH N 2 H O H
HO OH O
OH OH
OH
OH O
O 2 O HO O HO O O O HO O
OH O
O OH
H 2O
Rx-ID: 25669687 View in Reaxys Yield 93 % Conditions & References Example Name 5
23/55
2011-04-19 08:56:52
Examples 2 to 6: Preparation of azithromycin L-malate monohydrate from L-malic acidThe procedure of Example 1 was repeated except that azithromycin, L-malic acid and the solvent as shown in Table 3 were used, to obtain the title compound. Table 3 in acetone, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys 65 % Example Name 6 Examples 2 to 6: Preparation of azithromycin L-malate monohydrate from L-malic acidThe procedure of Example 1 was repeated except that azithromycin, L-malic acid and the solvent as shown in Table 3 were used, to obtain the title compound. Table 3 in ethanol, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys 53 - 90 % Example Name 1; 4 Example 1: Preparation of azithromycin L-malate monohvdrate from L-malic acid 100.Og of azithromycin dihydrate (127mmol) was dissolved in 1,000 ml of 95percent 2-propanol, and 34.1g of L-malic acid (254mmol) having an optical purity of 99.7percent ee was added thereto, followed by stirring the resulting solution overnight at room temperature and then for 2 hours at 0 to 5 C . The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45 C, to obtain 118.3 g of the title compound (yield: 90percent) as a white crystal.Examples 2 to 6: Preparation of azithromycin L-malate monohydrate from L-malic acidThe procedure of Example 1 was repeated except that azithromycin, L-malic acid and the solvent as shown in Table 3 were used, to obtain the title compound. Table 3 in isopropyl alcohol, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
N HO OH
O 2 HO HO O OH HO HO 3 OH O O N
HO OH O H O
HO HO O O O
OH
HO OH
O O
O OH
OH
O O O
O
O H
O O
OH
Rx-ID: 23234067 View in Reaxys Yield Conditions & References Example Name 4 Example Title Example 4. Preparation of azithromycin citrate 20g of azithromycin dihydrate and 3.5g of citric acid monohydrate are dissolved at ambient temperature in 50 ml of ethanol, filtered and the solvent is evaporated at low pressure. 24.9g of a white solid is obtained, containing up to 2. 0percent of ethanol and up to 7percent of water. The X-ray diffraction spectrum confirms that it is an amorphous product (Fig. 10). Figures 10,11 and 12 show the X-ray diffraction spectrum, the carbon 13 nuclear magnetic resonance spectrum (13C-NMR) in solid state and the IR spectrum, recorded on KBr tablet, respectively. in ethanol, T= 20 C Patent; QUIMICA SINTETICA, S.A.; WO2004/106355; (2004); (A1) English View in Reaxys Example Name 5 Example Title Example 5. Preparation of azithromycin citrate 20g of azithromycin dihydrate and 3. 5g of citric acid are added to 50 ml of water. The mixture is stirred at ambient temperature and the insoluble material filtered. The solution is concentrated at low pressure to a KF of around 5percent, yielding 23. LG of azithromycin citrate. Figures XIII, XIV and XV show the X-ray diffraction spectrum, the carbon 13
24/55
2011-04-19 08:56:52
nuclear magnetic resonance spectrum (13C-NMR) in solid state and the IR spectrum, recorded on KBr tablet, respectively.Example 6. Preparation of azithromycin citrate solutions Azithromycin citrate solutions are prepared by adding 20g of azithromycin, 3.5g of citric acid and the corresponding amount of water (35 to 94g of water), stirring at ambient temperature for a time ranging between 30 and 60 minutes, and finally filtering to remove insoluble material. The solution is stable at ambient temperature. in water, T= 20 C Patent; QUIMICA SINTETICA, S.A.; WO2004/106355; (2004); (A1) English View in Reaxys
O OH O O
O
OH O
O OH O HO O O
OH O
HO N H O OH O OH N
N OH O
O OH N
Rx-ID: 3948421 View in Reaxys Yield 86.9 % Conditions & References With formic acid in chloroform, water, Time= 10h, Heating Djokic, Slobodan; Kobrehel, Gabrijela; Lopotar, Nevenka; Kamenar, Boris; Nagl, Ante; Mrvos, Draginja; Journal of Chemical Research, Miniprint; nb. 5; (1988); p. 1239 - 1261 View in Reaxys
N N HO OH O O O O OH O O O
HO
N N HO OH OH O O O O O H O
OH HO
OH HO
O OH H 2O
Rx-ID: 23143267 View in Reaxys Yield Conditions & References Example Name 2.A Example Title Example 2; Preparation of the Orthorhombic Pseudopolymorph of Formula Ib (S = tert-butanol); (Method A) Crude [9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN] A (10.0 g, having a water conternt of 5.7percent) was dissolved in 20 ml tert-butanol at a temperature of [60.deg.C.] The solution was treated with actived carbon, filtered, and cooled to room temperature over a period of 2 hours. The precipitated crystals were allowed to stand at room temperature for a further 15 hours. The crystals were isolated and dried at atmospheric pressure and room temperature to constant weight. The product was lO. Og of a crystalline orthorhombic isostructural pseudopolymorph of Formula Ib (S = tert-butanol). The water content was 2.17percent, and the [TERT-] butanol content was 8.6percent. Upon single x-ray diffraction analysis, the orthorhombic pseudopolymorph was characterized as identified in Table 1 Figure 3. With water, T= 60 C Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
25/55
2011-04-19 08:56:52
N HO
HO O O
OH
N
OH O O O O OH N
OH
H
H O H
OH O OH
O 2 O OH OH O O HO O HO O HO O
HO O
OH O
O OH
H 2O
Rx-ID: 25669686 View in Reaxys Yield 89 % Conditions & References Example Name 3 Examples 2 to 6: Preparation of azithromycin L-malate monohydrate from L-malic acidThe procedure of Example 1 was repeated except that azithromycin, L-malic acid and the solvent as shown in Table 3 were used, to obtain the title compound. Table 3 in isopropyl alcohol, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
N N HO
O HO OH O OH
N
OH HO OH
HO N OH
O O O O
O 2 O O OH OH O O HO HO O HO O
OH O
O OH
Rx-ID: 29012842 View in Reaxys Yield Conditions & References Example Name 8 Example Title Preparation of Azithromycin L-Malate Monohydrate from DL-Malic Acid 100.0 g of azithromycin dihydrate (127 mmol) was dissolved in 1,000 ml of 95percent 2-propanol, and 34.1 g of DLmalic acid (254 mmol, an optical purity of 1.7percent ee in favor of L-malic acid) was added thereto, followed by stirring the resulting solution overnight at room temperature, and then, for 2 hours at 0 to 5.deg. C. The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45.deg. C., to obtain 61.8 g of white crystalline powders (yield: 47percent).M.P.: 170174.deg. C.Specific rotation, []D 20: -33.7.deg. (c=1, methanol)Moisture content (Karl-Fisher titrator): 1.85percentOptical purity of malic acid after salt formation (HPLC): 80.0percent ee in favor of L-malic acid56.0 g of the crystalline powders obtained above was recrystallized from 95percent 2-propanol, to obtain 45.2 g of the title compound (yield: 80percent).M.P.: 172175.deg. C.Specific rotation, []D 20: -33.0.deg. (c=1, methanol)Moisture content (Karl-Fisher titrator): 1.81percentOptical purity of malic acid (HPLC): 98.9percent ee of L-malic acidXPRD and IR absorption spectra of the compound thus obtained were the same as those of Example 1. in water, isopropyl alcohol, T= 0 - 20 C Patent; Hanmi Pharm Co., Ltd; US2009/318375; (2009); (A1) English View in Reaxys
26/55
2011-04-19 08:56:52
N O HO
HO
N
HO
N O HO HO
HO
HO O O O O
O O
OH O
O O
O O
OH
Rx-ID: 16861003 View in Reaxys Yield Conditions & References Reaction Steps: 2 1: 66 percent / H2 / PtO2 / acetic acid / 2 h / 51714.8 Torr 2: 98 percent / H2O; CHCl3 / 1.5 h / 70 C With hydrogen, platinum(IV) oxide in chloroform, water, acetic acid Wilkening, Robert R.; Ratcliffe, Ronald W.; Doss, George A.; Mosley, Ralph T.; Ball, Richard G.; Tetrahedron; vol. 53; nb. 50; (1997); p. 16923 - 16944 View in Reaxys
N N HO OH OH O O O O O H O
O O
N N HO OH OH HO
OH HO
O O O
O OH H 2O
OH
Rx-ID: 23163718 View in Reaxys Yield Conditions & References Example Name 14 Example Title Example 14; Preparation of Stable Amorphous [9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A,] from the Pseudopolymorph Ib (S=tert-butanol) The orthorhombic pseudopolymorph of Formula Ib (S = tert-butanol) obtained according to Example 2, was dried at [80.deg.C] under a reduced pressure of 13 Pa to constant weight. The yield and purity of the stable amorphous 9deoxo-9a-aza-9a-methyl-9a-homoerythromycin A thus obtained were identical to those in Example 11 , T= 80 C , p= 0.0975098Torr Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys Example Name 16 Example Title Example 16; Preparation of Stable Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, from the Pseudopolymorph Ib (S=tert-butanol) The orthorhombic pseudopolymorph of Formula Ib (S = tert-butanol), obtained according to Example 2, was sublimed at a temperature of [95.deg.C] under a reduced pressure of 1 Pa to constant weight. The yield and purity of the stable amorphous 9-deoxo-9a-aza-9a-methyl-9a- homoerythromycin A thus obtained were identical to those of Example 11 , T= 95 C , p= 0.00750075Torr Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
27/55
2011-04-19 08:56:52
N HO HO 0.5 O OH O O O OH OH O O N
HO O O
OH
O OH H O H
O OH
Rx-ID: 23333622 View in Reaxys Yield 6% Conditions & References Example Name 3 An identical test was also performed using form F azithromycin. The calculated solvent levels were again used to create solutions of these single components in water and used to constitute samples of POS formulation I using form F. The constituted drug suspensions were stored at room temperature for 24-hours, before being filtered and analyzed by SSNMR for quantification of azithromycin form change over this interval. POS formulation II was constituted with water and stored identically to serve as a control for this experiment. The design and results of this investigation can be seen in Table 9. [Table 9.] Effects of Flavoring Components Upon Azithromycin Form F Conversion Form F POS FormulationConstitution Medium (18 mL)SS-NMR Evaluation after 24 hrs constitutionpercentFpercentApercentG Formulation IIWater05941Formulation I0.922 mg/ml 3-methyl-butyl acetate000Formulation I0.0577 mg/ml benzaldehyde000Formulation I1.666 mg/ml 3-methyl-butyl acetate050Formulation I0.922 mg/ml 3-methyl-butyl acetate + 0.0577 mg/ml benzaldehyde060 Form F also demonstrated form conversion in the presence of organic flavoring components including 3-methyl-butyl acetate, either separately or in combination with benzaldehyde. It was also observed during this experiment that form F azithromycin had a tendency to convert to form G or other forms. With iso-pentyl acetate, water, benzaldehyde, Time= 24h, T= 20 C , Reactivity (does not react) Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 3 An identical test was also performed using form F azithromycin. The calculated solvent levels were again used to create solutions of these single components in water and used to constitute samples of POS formulation I using form F. The constituted drug suspensions were stored at room temperature for 24-hours, before being filtered and analyzed by SSNMR for quantification of azithromycin form change over this interval. POS formulation II was constituted with water and stored identically to serve as a control for this experiment. The design and results of this investigation can be seen in Table 9. [Table 9.] Effects of Flavoring Components Upon Azithromycin Form F Conversion Form F POS FormulationConstitution Medium (18 mL)SS-NMR Evaluation after 24 hrs constitutionpercentFpercentApercentG Formulation IIWater05941Formulation I0.922 mg/ml 3-methyl-butyl acetate000Formulation I0.0577 mg/ml benzaldehyde000Formulation I1.666 mg/ml 3-methyl-butyl acetate050Formulation I0.922 mg/ml 3-methyl-butyl acetate + 0.0577 mg/ml benzaldehyde060 Form F also demonstrated form conversion in the presence of organic flavoring components including 3-methyl-butyl acetate, either separately or in combination with benzaldehyde. It was also observed during this experiment that form F azithromycin had a tendency to convert to form G or other forms. With iso-pentyl acetate, water, Time= 24h, T= 20 C , Reactivity (does not react) Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than
28/55
2011-04-19 08:56:52
100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, polyvinylpyrrolidone, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension
29/55
2011-04-19 08:56:52
determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, cellulose acetate phthalate, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, hydroxypropyl methylcellulose, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with
30/55
2011-04-19 08:56:52
18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, carboxymethylcellulose sodium, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal.
31/55
2011-04-19 08:56:52
(R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With hydroxypropyl methylcellulose acetate succinate, water, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys
HN
O OH H
HO O HO O O
N HO
N O HO HO
HO
HO HO O O
O O
OH O
O O
O O
OH
Rx-ID: 4926124 View in Reaxys Yield 98 % Conditions & References in chloroform, water, Time= 1.5h, T= 70 C Wilkening, Robert R.; Ratcliffe, Ronald W.; Doss, George A.; Mosley, Ralph T.; Ball, Richard G.; Tetrahedron; vol. 53; nb. 50; (1997); p. 16923 - 16944 View in Reaxys
NZ HO HO O O
HO
N HO
O
HO O HO O O
HO O O
O O O O O OH
OH O
Rx-ID: 16859763 View in Reaxys Yield Conditions & References Reaction Steps: 3 1: 21 percent / nitromethane / 2 h / 100 C 2: 66 percent / H2 / PtO2 / acetic acid / 2 h / 51714.8 Torr 3: 98 percent / H2O; CHCl3 / 1.5 h / 70 C With hydrogen, platinum(IV) oxide in nitromethane, chloroform, water, acetic acid Wilkening, Robert R.; Ratcliffe, Ronald W.; Doss, George A.; Mosley, Ralph T.; Ball, Richard G.; Tetrahedron; vol. 53; nb. 50; (1997); p. 16923 - 16944 View in Reaxys
32/55
2011-04-19 08:56:52
N N HO OH O O O O O O H O
O O
N N HO OH OH HO
OH HO
O O O
O OH H 2O
OH
Rx-ID: 23163717 View in Reaxys Yield Conditions & References Example Name 13 Example Title Example 13; Preparation of Stable Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, from the Pseudopolymorph la (S=1, 4-dioxane) The orthorhombic pseudopolymorph of Formula la (S = 1,4-dioxane) obtained according to Example 1, was dried at [50.deg.C] and a reduced pressure of 0.1 kPa to constant weight. The yield and purity of the stable amorphous [9DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN] A thus produced were identical to those of Example 11. , T= 50 C , p= 0.750075Torr Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
N N HO OH O O O O O H O
O O
N N HO OH OH HO
OH HO
O O O
O OH H 2O
OH
Rx-ID: 23163720 View in Reaxys Yield Conditions & References Example Name 15 Example Title Example 15; Preparation of Stable Amorphous [9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A,] from the Pseudopolymorph Id (S=cyclohexane) The orthorhombic pseudopolymorph of Formula Id (S = cyclohexane) obtained according to Example 4, was dried at [80.deg.C] under a reduced pressure of 2 kPa to constant weight. The yield and purity of the stable amorphous 9deoxo-9a-aza-9a-methyl-9a-homoerythromycin A thus obtained were identical to those of Example 11 , T= 80 C , p= 15.0015Torr Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
33/55
2011-04-19 08:56:52
N N HO OH O O O O OH O O O OH HO
HO O O
OH
Rx-ID: 23751993 View in Reaxys Yield Conditions & References Example Name 3 The crude azithromycin prepared in Example 1 (105 kg) was dissolved in about 304 L ethanol (95percent) at about 70.deg. C. in a 800 L reaction vessel. The solution was then hot filtered through about 1 kg of Celite.(R)., and the filtrate was allowed to directly flow into about 304 kg of water in a 1,000-L reaction vessel. During the addition, the water temperature was maintained at about 20.deg. C. The resulting slurry was stirred for about 5 hours. The precipitate was filtered and washed with water, providing about 109.4 kg of wet precipitate (contained 35.42percent water (w/w)). The wet precipitate was slurried vigorously in about 700 L of water in a 1,000-L reaction vessel for about 5 hours at room temperature. The slurry was filtered, washed with water, and dried in stages to provide about 68.2 kg of crystalline azithromycin monohydrate. The water content, ethanol content, purity, stability, hygroscopicity, and other parameters are presented in Tables 1 and 2. Table 1 shows that the crystalline azithromycin monohydrate was stable and nonhygroscopic for 3 months when stored at 25.deg. C. and 60percent relative humidity. Table 2 shows that the crystalline azithromycin monohydrate was stable and non-hygroscopic for 3 months when stored at 40.deg. C. and 75percent relative humidity. With water in ethanol, Time= 10h, T= 20 - 70 C , Industry scale, Purification / work up Patent; Gutman, Daniella; Shahal, Leah; US2006/63725; (2006); (A1) English View in Reaxys
N
HO N
HO O O
OH
O OH HO
OH O 2 O
OH
HO O OH OH O HO
HO O O OH O O
O OH
H 2O
Rx-ID: 25678887 View in Reaxys Yield 47 % Conditions & References Example Name 8 Example 8: Preparation of azithromycin L-malate monohvdrate from DL-malic acid100.0 g of azithromycin dihydrate (127mmol) was dissolved in 1,000 mi of 95percent 2-propanol, and 34.1g of DL-malic acid (254mmol5 an optical purity of 1.7percent ee in favor of L-malic acid) was added thereto, followed by stirring the resulting solution overnight at room temperature, and then, for 2 hours at 0 to 5 C . The precipitate formed was filtered, washed with cold 2-propanol, and dried at 45 C, to obtain 61.8 g of white crystalline powders (yield: 47percent). in isopropyl alcohol, T= 0 - 20 C , Product distribution / selectivity Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
34/55
2011-04-19 08:56:52
N HO HO N OH O 2 O OH OH O O O O H 2O HO O HO O HO 2 O O OH OH OH O O HO HO O HO O O OH O N
OH O
Rx-ID: 25686322 View in Reaxys Yield Conditions & References Example Name A Reference Example 1 : Preparation of azithromycin L-malate anhydrateMethod A10.0g of azithromycin L-malate monohydrate obtained in one of Examples 1 to 8 was dried under a reduced pressure (lmmHg) at 100 C for 10 hours, to obtain the title compound as white powders. Patent; HANMI PHARM. CO., LTD.; WO2006/132486; (2006); (A1) English View in Reaxys
N HO HO 0.5 OH O O O O OH OH O O N
HO O O
OH
O OH H O H
O OH
Rx-ID: 23333624 View in Reaxys Yield Conditions & References Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellu-
35/55
2011-04-19 08:56:52
lose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With Igepal.(R).CO-630, water, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, polyvinylpyrrolidone, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4
36/55
2011-04-19 08:56:52
This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With Pluronic.(R).F-68NF, water, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at
37/55
2011-04-19 08:56:52
room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, hydroxypropyl cellulose, Time= 24h, T= 20 C , Conversion of starting material Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys Example Name 4 This example demonstrates that when excipients, which can decrease surface tension, such as anionic and non-ionic surfactants and surface active polymers, are incorporated into a POS formulation, the non-dihydrate azithromycin in suspension was stabilized against conversion. Forms F and M azithromycin were formulated into POS formulation II. A series of surfactants and polymers were then added to these formulations and the resulting samples constituted with 18mls of water. After 24-hours of room temperature storage the samples were filtered and analyzed by SS-NMR for quantitation of dihydrate species present. The data are presented in Tables 10 and 11 and are given as the percent that is converted to form A relative to a control sample. Thus, additives with conversion values greater than 100percent show that more non-dihydrate azithromycin was converted to form A than in the control sample while values less than 100percent show that the additive is decreasing the conversion to form A compared to the control sample. The control sample consisted of non-dihydrate azithromycin form F or form M in formulation II, which was shown to promote conversion to azithromycin dihydrate (form A). The control sample was constituted with water, stored and analyzed identically to the additive samples as described above. [Table 10.] Addition of Polymeric and Surfactant Components to Slow Form F Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Hydroxypropyl Methylcellulose Acetate Succinate143.73 23Hydroxypropyl Methylcellulose0.247.12 43Carboxymethylcellulose Sodium170.92 106Cellulose Acetate Phthalate1.551.33 136Polyvinylpyrrolidone168.32 1111Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3Surface tension of the saturated aqueous solution of the polymer determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.[Table 11.] Addition of Polymeric and Surfactant Components to Slow Form M Conversion AdditiveAdditive Level (percentw/v)Surface Tension (dyne/cm)percent Conversion to Form A Relative to the Control SampleSodium Dioctyl Sulfosuccinate125.61 0Sodium Lauryl Sulfate135.82 0Igepal. (R). CO-6301323 8Pluronic.(R). F68NF143.21 10Hydroxypropyl Cellulose0.3421 72Hydroxypropyl Methylcellulose0.4471 97Polyvinylpyrrolidone168.32 1071Literature Value (Johnson, Barbara A., Kreuter, Jorg and Zografi, George, "Effects of Surfactants and Polymers on Advancing and Receding Contact Angles" Colloids and Surfaces, 17 (1986) 325-342.)2Surface tension of an aqueous solution of the polymer at the concentration used in the suspension determined with a Kruss Tensiometer using the Wilhemy plate method at room temperature.3GAF Chemicals Corp., Technical Bulletin 2303-015R2 (1986) This example showed that additives which are surface active such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate and sodium dioctyl sulfosuccinate are effective in slowing the conversion of form F to the dihydrate form. The anionic surfactants, sodium lauryl sulfate and sodium dioctyl sulfosuccinate, are also shown as effective for inhibiting conversion of a second nondihydrate azithromycin form (form M). The cellulosic polymers, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and the polyoxyethylene-polyoxypropylene copolymer Pluronic.(R). F68NF and the nonionic surfactant nonylphenoxy polyoxyethylene Igepal.(R). CO-630 were also found to slow the conversion of non-dihydrate azithromycin form M. The effectiveness of these additives is related to their surface activity as shown in Tables 10 and 11. With water, hydroxypropyl methylcellulose, Time= 24h, T= 20 C , Conversion of starting material
38/55
2011-04-19 08:56:52
Patent; Pfizer Products Inc.; EP1498141; (2005); (A1) English View in Reaxys
N N HO OH OH HO
O
O
O O O
O OH
Rx-ID: 25840860 View in Reaxys Yield Conditions & References Example Name 3.a; 3.b Example 3: Preparation of azithromycin:; (a) Preparation of boron complex of cyclic amine of Formula III:; 6,9-miino ether (Formula-II) (100 g) was suspended in water (1.0 lit). The reaction mixture was cooled to 0-5.deg.C. To the resulting reaction mixture, chilled aqueous solution of sodium borohydride (18.0 g in 200ml water) was added at temperature between 0-5.deg.C and pH was maintained between 6.0 -8.0 with formic acid. After completion of the borohydride addition, the reaction mixture was stirred at 0-50.deg.C for 1 hr and then at room temperature for 10 hrs. The pH was adjusted to 9.5 with sodium hydroxide solution and then aqueous layer was extracted with chloroform (300ml x 2). The combined chloroform extracts containing title compound a) was taken for the next step.; (b); The pH of the chloroform extract was adjusted to 5.0 to 5.5 with formic acid (17.0 g) and formaldehyde (17.0 g) and the resultant mass was refluxed for 10 hr. After completion of the reaction, water (500 ml) was added and the pH was brought to 4.0 with hydrochloric acid. The chloroform layer was separated and to the aqueous layer, methanol (500 ml) was added. The resulting reaction mixture was cooled to -10 to - 2O0C and the pH was adjusted to 1.0 with hydrochloric acid. Then reaction mixture was basified with sodium hydroxide and extracted with chloroform (300 ml x 2). The combined chloroform extracts were concentrated to dryness and crystallized with isopropyl alcohol/ water or acetonitrile / water mixture to get the title compound. Yield: 65 g. Purity: 98.0percent (By HPLC) Stage 1: With sodium tetrahydroborate, formic acid in water, Time= 11h, T= 0 - 50 C , pH= 6 - 8 Stage 2: With sodium hydroxide in water, pH= 9.5 Stage 3: With hydrogenchloride, sodium hydroxide, formic acid, Product distribution / selectivity, more than 3 stages Patent; WOCKHARDT LTD; PUROHIT, Manish; MUKARRAM, Siddiqui Mohammad Jaweed; NAITHANI, Pankaj Kumar; POKALWAR, Raj Kumar; SUTARIYA, Prakash Maganlal; WO2007/80507; (2007); (A2) English View in Reaxys
H O H
N O HO
(v3)
OH N
N O HO HO HO O N OH
O O
HO O
O O O
O
O OH
O O O OH O
Rx-ID: 17062935 View in Reaxys Yield Conditions & References Reaction Steps: 2 1: 70.5 percent / H2SO4 / acetonitrile; H2O / 0.5 h / 15 C / pH 2 2: 84.2 percent / water / acetone / 24 h / Ambient temperature With sulfuric acid, water in water, acetone, acetonitrile Bayod-Jasanada, Miguel; Carbajo, Rodrigo J.; Lopez-Ortiz, Fernando; Journal of Organic Chemistry; vol. 62; nb. 21; (1997); p. 7479 - 7481 View in Reaxys
39/55
2011-04-19 08:56:52
N
NZ HO HO O O O O O OH O O O HO N
N HO OH O O O O OH O O O OH HO
Rx-ID: 16859753 View in Reaxys Yield Conditions & References Reaction Steps: 2 1: nitromethane / 2 h / 100 C 2: 1.) NaBH4 / 1.) ethylene glycol, 0 deg C -> room temperature; room temperature, 5 h, 2.) H2O, CHCl3 With sodium tetrahydroborate in nitromethane Wilkening, Robert R.; Ratcliffe, Ronald W.; Doss, George A.; Mosley, Ralph T.; Ball, Richard G.; Tetrahedron; vol. 53; nb. 50; (1997); p. 16923 - 16944 View in Reaxys
HN N HO
O OH H
OH N N
OH O O O O
OH OH
OH
HO
OH O O O
OH OH
O O
10 H 2O
10
O O
OH
O OH
Rx-ID: 23655232 View in Reaxys Yield 70 - 94 % Conditions & References Example Name 1; 2; 3; 4 EXAMPLE 1; Azaerythromycin 100 g (96.0percent) is suspended in Isopropanol (300 ml) and the temperature is raised to 60-75.deg. C. Methylating solution (23 ml formic acid (Assay=99percent) and 23 ml formaldehyde 35percent) are added over a period of 4-5 hours. The mixture is stirred for 12 hrs and then cooled to 40.deg. C. The sodium hydroxide solution (25percent w/v, 60-70 ml) is added in the reaction mixture and stirred for 20 minutes. Aqueous layer is separated and extracted with 75 ml isopropanol. Combined organic layer (Isopropanol) is distilled out up to foamy materials. Isopropanol (300 ml) is added and the reaction mass is heated to 45-50.deg. C. Combine organic layer is clarified by filtration. To the filtered isopropanol solution, water (450 ml) is added to precipitate azithromycin monohydrate isopropanol clathrate. The mass is stirred for 6 hrs at 25 to 30.deg. C. The resulting product is filtered and washed with 50:50 mixture of isopropanol-water. The product is dried under vacuum (1 to 10 mm Hg) at 25-50.deg. C. temp for 2-10 hrs. Yield 89.0 gms (89percent) Isopropanol: 3.26percent. Water: 2.91percent.; EXAMPLE 2; Azaerythromycin 100 g (96.0percent) is suspended in Isopropanol (300 ml) and the temperature is raised to 60-65.deg. C. Methylating solution (23.0 ml formic acid (Assay=99percent) and 23 ml formaldehyde 35percent) are added over a period of 4-5 hours. The mixture is stirred for 12 hrs and then the mass is cooled to 40.deg. C. The sodium hydroxide solution (25percent w/v, 60-70 ml) is added in the reaction mixture and stirred for 20 minutes. Aqueous layer is separated and extracted with 75 ml isopropanol. Combined organic layer (Isopropanol) is clarified by filtration. Water (570 ml) is added in 15-30 minutes and the reaction mass is stirred for 6-12 hrs at 25 to 30.deg. C. temp. The resulting product is filtered and washed with 50:50 mixture of isopropanol-water. The product is dried under vacuum at 45-50.deg. C. temp under reduced pressure. The product is dried under vacuum (1 to 10 mm Hg) at 25-50.deg. C. temp for 2-10 hrs. Yield 94 gms (94percent) Isopropanol: 3.19percent Water: 2.5percent; EXAMPLE 3; Azaerythromycin 100 g (89.0percent purity) is suspended in Isopropanol (300 ml) at temperature of 25-30.deg. C. To this solution formic acid (16.6 gms, 2.654 mole) and Paraformaldehyde (10.0 gms, 2.45 mole) are added and the temperature is raised up to 65-70.deg. C. The mixture is stirred for 3-6 hrs and the mass is cooled to 40.deg. C. The mixture is stirred for 12 hrs and cooled to 40.deg. C. The sodium hydroxide solution (25percent w/v, 60-70 ml) is added in the reaction mixture and stirred for 20 minutes. Aqueous layer is separated and extracted with 50 ml isopropanol. Combine organic layer (Isopropanol) is clarified by filtration and distilled isopropanol up to foamy materials., Isopropanol (300 ml) is added and the reaction mass is heated
40/55
2011-04-19 08:56:52
to 45-50.deg. C. Combine organic layer is clarified by filtration. To the filtered isopropanol solution, water (400 ml) is added to precipitate azithromycin monohydrate isopropanol clathrate. The mass is then stirred for 6-12 hrs at 25 to 30.deg. C. The resulting product is filtered and washed with 50:50 mixture of isopropanol-water. The product is dried under vacuum (1 to 10 mm Hg) at 25-50.deg. c. temp for 2-10 hrs. Yield 70.0 gms (70percent) Isopropanol: 3.36percent Water: 2.04percent; EXAMPLE 4; Azaerythromycin 100 g (purity=89percent) is suspended in isopropanol (300 ml) at temperature of 25-35.deg. C. To this solution formic acid (16.6 gms, 2.65 mole) and Paraformaldehyde (10.0 gms, 2.45 mole) are added and the temperature of reaction mass is raised to 65-70.deg. C. The mixture is stirred for 3-6 hrs and cooled to 40.deg. C. The sodium hydroxide solution (25percent w/v, 60-70 ml) is added in the reaction mixture and stirred for 20 minutes. Aqueous layer is separated and extracted with 50 ml isopropanol. Combine organic layer (Isopropanol) is clarified by filtration. To the filtered isopropanol solution, water (400 ml) is added to precipitate azithromycin monohydrate isopropanol clathrate. The mass is then stirred for 6-12 hrs at 25 to 30.deg. C. The resulting product is filtered and washed with 50:50 mixture of isopropanol-water. The product is dried under vacuum (1 to 10 mm Hg) at 25-50.deg. C. temp for 2-10 hrs. Yield 80 gms (80percent) Isopropanol: 3.14percent Water: 2.56percent Stage 1:, Time= 3 - 17h, T= 60 - 75 C Stage 2: With sodium hydroxide, water, Time= 0.333333h, T= 40 C , Product distribution / selectivity Patent; ALEMBIC LIMITED; US2006/19908; (2006); (A1) English View in Reaxys
N N
O
O OH
N O HO
HO
N
HO OH
OH HO
O
H
HO O O O O
O
O
O O O
OH O
O OH
Rx-ID: 4926123 View in Reaxys Yield Conditions & References With sodium tetrahydroborate, 1.) ethylene glycol, 0 deg C -> room temperature; room temperature, 5 h, 2.) H2O, CHCl3, Multistep reaction Wilkening, Robert R.; Ratcliffe, Ronald W.; Doss, George A.; Mosley, Ralph T.; Ball, Richard G.; Tetrahedron; vol. 53; nb. 50; (1997); p. 16923 - 16944 View in Reaxys
HO O O
OH
Rx-ID: 24037520 View in Reaxys Yield 95 % Conditions & References Example Name 1D To 10 gm of Azithromycin dihydrate, 30 ml acetone was added for 30 minutes with stirring till the clear solution obtained. 0.3 gm charcoal was added to this solution and the mixture was stirred for 30 minutes and subsequently filtered. To the filtrate, 180 ml of water was added at 50.deg. to 55.deg. C within 12 hour. The aqueous filtrate was cooled to room temperature and then chilled to 0.deg. to 5.deg. C. Azithromycin dihydrate was filtered from the aqueous filtrate and washed with chilled water (0.deg. to 5.deg. C). Azithromycin dihydrate was dried at 65.deg. C. The yield and purity of Azithromycin dihydrate was 95 percent and 100 percent.Azithromycin dihydrate was characterized by IR (Refer Figure 2 of the Accompanying drawing)
41/55
2011-04-19 08:56:52
Stage 1: With carbon in water, acetone, Time= 1h Stage 2: in water, acetone, Time= 12h, T= 0 - 55 C , Purification / work up Patent; KOPRAN RESEARCH LABORATORIES LTD; WO2007/29266; (2007); (A2) English View in Reaxys Example Name 5 Example Title Azithromycin Dihydrate EXAMPLE 5 Azithromycin Dihydrate The title product, 0.5 Kg, prepared in Example 4, was dissolved in water, making the solution acidic (pH of 2.5 to 5.0) with dilute hydrochloric acid. After 20 minutes stirring the pH was raised with dilute sodium hydroxide and the solution was stirred for twelve hours. The product was crystallized as a white crystalline material in high purity. Yield: 0.48 Kg. Patent; Wockhardt Limited; US2003/139583; (2003); (A1) English View in Reaxys Example Title Preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate. Method A 25 g of crystalline azithromycin monohydrate are dissolved in 130 ml of tert-butanol heating at 30.deg. C. This solution is filtered and 130 ml of water are added over 6 h. The resulting mixture is taken to pH=11 by addition of NaOH 2N, cooled down below 10.deg. C. and subsequently stirred for 48-72 h. The crystals are collected by filtration and dried (80 mm Hg/25.deg. C.) to yield 15 g of azithromycin dihydrate. Patent; Astur-Pharma, S.A.; US6451990; (2002); (B1) English View in Reaxys Example Title Preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate. Method B 25 g of crystalline azithromycin monohydrate are dissolved in 50 ml of tert-butanol heating at 30.deg. C. This solution is filtered and discharged over a mixture of 500 ml of petroleum ether and 20 ml of water. The resulting mixture is cooled down below 10.deg. C. and subsequently stirred for 48-72 h. The crystals are collected by filtration and dried (80 mm Hg/25.deg. C.) to yield 12 g of azithromycin dihydrate IR(KBr), 1H-NMR (CDCl3), 13C-NMR (CDCl3), m/e, TLC and HPLC are identical to those of the previous example. Patent; Astur-Pharma, S.A.; US6451990; (2002); (B1) English View in Reaxys Example Name 1 Example Title Non-Hygroscopic Azithromycin Dihydrate Method A EXAMPLE 1 Non-Hygroscopic Azithromycin Dihydrate Method A The hygroscopic monohydrate of Preparation 1 (100 g; water-content:3.1percent), tetrahydrofuran (220 ml) and diatomaceous earth (5 g) were combined in a 500 ml Erlenmyer flask, stirred for 30 minutes and filtered with 20 ml of tetrahydrofuran wash. The combined filtrate and wash was transferred to a 3 liter round bottom flask. The solution was stirred vigorously and H2 O (2.0 ml) was added. After 5 minutes, hexane (1800 ml) was added over 5 minutes, with continued vigorous stirring. Following an 18 hour granulation period, title product was recovered by filtration with 1*10 ml hexane wash, and dried in vacuo to 4.6+-0.2percent H2 O by Karl Fischer, 89.5 g. Patent; Pfizer Inc.; US4963531; (1990); (A1) English View in Reaxys Example Name 1.B Example Title Method B Method B The hygroscopic monohydrate of Preparation 1 (197.6 g) and tetrahydrofuran (430 ml) were charged to a reactor and the mixture stirred to achieve a milky white solution. Activated carbon (10 g) and diatomaceous earth (10 g) were added and the mixture stirred for 15 minutes, then diluted with 800 ml of hexane and filtered with suction over a pad of diatomaceous earth with 250 ml of hexane for wash.
42/55
2011-04-19 08:56:52
The combined filtrate and wash was diluted to 2500 ml with hexane and warmed to 34.deg. C. With stirring, 24.7 ml of H2 O was added. The mixture was allowed to cool to room temperature, granulated for five hours and title product recovered and dried as in Method A, 177.8 g. The dihydrate melts sharply at 126.deg. C. (hot stage, 10.deg./minute); differential scanning calorimetry (heating rate, 20.deg. C./minute) shows an endotherm at 127.deg. C.; thermal gravimetric analysis (heating rate 30.deg. C./minute) shows a 1.8percent weight loss at 100.deg. C. and a 4.3percent weight loss at 150.deg. C.; ir (KBr) 3953, 3553, 3488, 2968, 2930, 2888, 2872, 2827, 2780, 2089, 1722, 1664, 1468, 1426, 1380, 1359, 1344, 1326, 1318, 1282, 1270, 1252, 1187, 1167, 1157, 1123, 1107, 1082, 1050, 1004, 993, 977, 955, 930, 902, 986, 879, 864, 833, 803, 794, 775, 756, 729, 694, 671, 661, 637, 598, 571, 526, 495, 459, 399, 374, 321 and 207 cm-1; [alpha]D 26 =-41.4.deg. (c=1, CHCl3) Anal Calcd. for C38 H72 N2 O12.2H 2 O: C, 58.14; H, 9.77; N, 3.57; OCH3, 3.95; H2 O, 4.59. Patent; Pfizer Inc.; US4963531; (1990); (A1) English View in Reaxys Example Name 1 Example Title EXAMPLE 1 EXAMPLE 1 Preparation of azithromycin dihydrate. 5g of crude azithromycin, prepared as described in EP 9803945.4, was dissolved in 22.6 ml of water and 2.4 ml of hydrochloric acid (6N) at a temperature of from 20.deg.C to 25.deg.C. To this solution was added 25 ml of acetone and 2.8 ml of 20percent (w/v) aqueous sodium hydroxide solution to adjust the pH to 9.8. After stirring for 5 hours at a temperature of from 20.deg.C to 25.deg.C the suspension was cooled to from 5.deg.C to 0.deg.C and stirred for 1 hour at this temperature. The resulting solid was collected by filtration, washed with water (3 times 5 ml of water cooled at 5.deg.C) and dried at 35-40.deg.C to give azithromycin dihydrate (3.3g). Patent; HOVIONE INTER LTD.; EP941999; (1999); (A2) English View in Reaxys Example Name 2 Example Title EXAMPLE 2 EXAMPLE 2 Preparation of azithromycin dihydrate. 5g of crude azithromycin was dissolved in 12.6 ml of water and 2.4 ml of hydrochloric acid (6N) at a temperature of from 20.deg.C to 25.deg.C. To this solution was added 35 ml of acetone and 2.8 ml of 20percent (w/v) aqueous sodium hydroxide solution to adjust the pH to 9.8. After stirring for 5 hours at a temperature of from 20.deg.C to 25.deg.C the suspension was cooled to from 5.deg.C to 0.deg.C and stirred for 1 hour at this temperature. The resulting solid was collected by filtration, washed with water (3 times 5 ml of water cooled at 5.deg.C) and dried at 35-40.deg.C to give azithromycin dihydrate (2.6g). Patent; HOVIONE INTER LTD.; EP941999; (1999); (A2) English View in Reaxys Example Name 3 Example Title EXAMPLE 3 EXAMPLE 3 Preparation of azithromycin dihydrate. 5g of crude azithromycin was dissolved in 32.6 ml of water and 2.4 ml of hydrochloric acid (6N) at a temperature of from 20.deg.C to 25.deg.C. To this solution was added 15 ml of acetone and 2.8 ml of 20percent (w/v) aqueous sodium hydroxide solution to adjust the pH to 9.8. After stirring for 29 hours at a temperature of from 20.deg.C to 25.deg.C the suspension was cooled to from 5.deg.C to 0.deg.C and stirred for 1 hour at this temperature. The resulting solid was collected by filtration, washed with water (3 times 5 ml of water cooled at 5.deg.C) and dried at 35-40.deg.C to give azithromycin dihydrate (4.6g). Patent; HOVIONE INTER LTD.; EP941999; (1999); (A2) English
43/55
2011-04-19 08:56:52
View in Reaxys Example Name 5 Example Title EXAMPLE 5 EXAMPLE 5 Conversion of azithromycin monohydrate to azithromycin dihydrate. Azithromycin monohydrate (5g) was suspended in 50 ml of water/acetone (30:70 by weight) and stirred for 24 hours at 20-25.deg.C. The solid was collected by filtration, and dried at 35-40.deg.C to give azithromycin dihydrate (4.8g). Patent; HOVIONE INTER LTD.; EP941999; (1999); (A2) English View in Reaxys Example Name 1.A Example Title Method A Method A The hygroscopic monohydrate of Preparation 1 (100 g; water-content:3.1percent), tetrahydrofuran (220 ml) and diatomaceous earth (5 g) were combined in a 500 ml Erlenmyer flask, stirred for 30 minutes and filtered with 20 ml of tetrahydrofuran wash. The combined filtrate and wash was transferred to a 3 liter round bottom flask. The solution was stirred vigorously and H2O (2.0 ml) was added. After 5 minutes, hexane (1800 ml) was added over 5 minutes, with continued vigorous stirring. Following an 18 hour granulation period, title product was recovered by filtration with 1 x 10 ml hexane wash, and dried in vacuo to 4.6+-0.2percent H2O by Karl Fischer, 89.5 g. Patent; PFIZER INC.; EP307128; (1989); (A2) English View in Reaxys Example Name 1.B Example Title Method B Method B The hygroscopic monohydrate of Preparation 1 (197.6 g) and tetrahydrofuran (430 ml) were charged to a reactor and the mixture stirred to achieve a milky white solution. Activated carbon (10 g) and diatomaceous earth (10 g) were added and the mixture stirred for 15 minutes, then diluted with 800 ml of hexane and filtered with suction over a pad of diatomaceous earth with 250 ml of hexane for wash. The combined filtrate and wash was diluted to 2500 ml with hexane and warmed to 34.deg.C. With stirring, 24.7 ml of H2O was added. The mixture was allowed to cool to room temperature, granulated for five hours and title product recovered and dried as in Method A, 177.8 g. The dihydrate melts sharply at 126.deg.C (hot stage, 10.deg./minute); differential scanning calorimetry (heating rate, 20.deg.C/minute) shows an endotherm at 127.deg.C; thermal gravimetric analysis (heating rate 30.deg.c/minute) shows a 1.8percent weight loss at 100.deg.C and a 4.3percent weight loss at 150.deg.C; ir (KBr) 3953, 3553, 3488, 2968, 2930, 2888, 2872, 2827, 2780, 2089, 1722, 1664, 1468, 1426, 1380, 1359, 1344, 1326, 1318, 1282, 1270, 1252, 1187, 1167, 1157, 1123, 1107, 1082, 1050, 1004, 993, 977, 955, 930, 902, 986, 879, 864, 833, 803, 794, 775, 756, 729, 694, 671, 661, 637, 598, 571, 526, 495, 459, 399, 374, 321 and 207 cmmin 1; [alpha] [26/D ] = -41.4.deg. (c=1, CHCl3). Anal. Calcd. for C3 8H7 2N2O1 2.2H2O: C, 58.14; H, 9.77; N, 3.57; OCH3, 3.95; H2O, 4.59. Found: C, 58.62; H, 9.66; N, 3.56; OCH3, 4.11; H2O, 4.49. Patent; PFIZER INC.; EP307128; (1989); (A2) English View in Reaxys Example Name 1.A Example Title Method A Method A The hygroscopic monohydrate of Preparation 1 (100 g; water-content:3.1percent), tetrahydrofuran (220 ml) and diatomaceous earth (5 g) were combined in a 500 ml Erlenmyer flask, stirred for 30 minutes and filtered with 20 ml of tetrahydrofuran wash. The combined filtrate and wash was transferred to a 3 liter round bottom flask. The solution was stirred vigorously and H2O (2.0 ml) was added. After 5 minutes, hexane (1800 ml) was added over 5 minutes, with continued vigorous stirring.
44/55
2011-04-19 08:56:52
Following an 18 hour granulation period, title product was recovered by filtration with 1*10 ml hexane wash, and dried in vacuo to 4.6+-0.2percent H2O by Karl Fischer, 89.5 g. Patent; Pfizer Inc.; US6268489; (2001); (B1) English View in Reaxys Example Name 1.B Example Title Method B Method B The hygroscopic monohydrate of Preparation 1 (197.6 g) and tetrahydrofuran (430 ml) were charged to a reactor and the mixture stirred to achieve a milky white solution. Activated carbon (10 g) and diatomaceous earth (10 g) were added and the mixture stirred for 15 minutes, then diluted with 800 ml of hexane and filtered with suction over a pad of diatomaceous earth with 250 ml of hexane for wash. The combined filtrate and wash was diluted to 2500 ml with hexane and warmed to 34.deg. C. With stirring, 24.7 ml of H2O was added. The mixture was allowed to cool to room temperature, granulated for five hours and title product recovered and dried as in Method A, 177.8 g. Patent; Pfizer Inc.; US6268489; (2001); (B1) English View in Reaxys
N N HO OH O O O O OH O O O OH HO
Rx-ID: 22898599 View in Reaxys Yield 100 % Conditions & References Example Name 11-16 Purification / work up Patent; Pliva Pharmaceutical Industry, Incorporated; US2004/92460; (2004); (A1) English View in Reaxys 98% Example Name 6 Example Title N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A EXAMPLE 6 N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A A solution of N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A desosaminyl-N-oxide (15 mg) in ethanol (5 ml) was hydrogenated at 2 psi using 5 mg 5percent Pd-C catalyst for 3 hours. Filtration of the catalyst and solvent removal in vacuo produced the title compound (98percent yield) as a colorless foam. Its 1 Hnmr and TLC Rf values were identical to those of the product of Example 3. Patent; Pfizer Inc.; US4474768; (1984); (A1) English View in Reaxys 95 % Example Name 1D Example 1 D; Purification of Azithromycin dihydrate; To 10 gm of Azithromycin dihydrate, 30 ml acetone was added for 30 minutes with stirring till the clear solution obtained. 0.3 gm charcoal was added to this solution and the mixture was stirred for 30 minutes and subsequently filtered. To the filtrate, 180 ml of water was added at 50.deg. to 55.deg. C within 12 hour. ThI aqueous filtrate was cooled to room temperature and then chilled to 0.deg. to 5.deg. C. Azithromycin dihydrate was filtered from the aqueous filtrate and washed with chilled water (0.deg. to 5.deg. C). Azithromycin dihydrate was dried at 65.deg. C. The yield and purity of Azithromycin dihydrate was 95 percent and 100 percent.Azithormycin dihydrate was characterized by IR (Refer Figure 2 of the Accompanying drawing).
45/55
2011-04-19 08:56:52
in water, acetone, Time= 13h, T= 0 - 55 C , Purification / work up Patent; KOPRAN RESEARCH LABORATORIES LTD; WO2007/15265; (2007); (A2) English View in Reaxys Example Name 2.B Example Title 2B 2B Azithromycin dihydrate is slowly added to one volume of warm ethanol, about 70.deg. C., and stirred to complete dissolution at 65 to 70.deg. C. The solution is allowed to cool gradually to 2-5.deg. C. and ethanol volume may be reduced by vacuum distillation. Seeds of Form F 1-2percent wt may be introduced to facilitate the crystallization. After stirring up to 2 hours the crystalline solids are collected by vacuum filtration. The isolation of the crystals yields substantially pure form F azithromycin, form F azithromycin substantially free of form G azithromycin and form F azithromycin substantially free of azithromycin dihydrate. Patent; Li, Zheng J.; Trask, Andrew V.; US2003/162730; (2003); (A1) English View in Reaxys Example Name 6 Example Title Preparation of Form N Example 6 Preparation of Form N Two volumes of ethanol and 2 volumes of isopropanol were added to a reaction vessel and heated to 50.deg. C. Azithromycin form A was added with stirring to the heated ethanol/isopropanol mixture to yield a clear solution. The reaction vessel was charged with 2 volumes distilled water (ambient temperature). Stirring was continued at 50.deg. C. and solid form N azithromycin precipitated after approximately 1 hr. Heating was discontinued 5 hours after the addition of the water. The slurry was allowed to cool to ambient temperature. Precipitated form N azithromycin was collected by filtration and dried for 4 hours in vacuum oven at 45.deg. C. Patent; Li, Zheng J.; Trask, Andrew V.; US2003/162730; (2003); (A1) English View in Reaxys Example Name 7 Example Title Preparation of Amorphous Azithromycin Example 7 Preparation of Amorphous Azithromycin Crystalline form A azithromycin was heated to 110-120.deg. C. in an oven for overnight under vacuum. The amorphous solids were collected and stored with desiccant as needed. Patent; Li, Zheng J.; Trask, Andrew V.; US2003/162730; (2003); (A1) English View in Reaxys Example Name 6 Example Title Anhydrous Azithromycin EXAMPLE 6 Anhydrous Azithromycin The azithromycin dihydrate, prepared in Example 5, or the azithromycin monohydrate, prepared in Example 4, about 500 g, was dissolved in isopropanol, 3 L. The solution was heated and the alcohol was distilled to remove the water. After the solvent was removed the residue was dried under vacuum to provide the anhydrous azithromycin. Yield 470 g; Purity>=96percent. Patent; Wockhardt Limited; US2003/139583; (2003); (A1) English View in Reaxys In a preferred embodiment of the invention the antibiotic is selected from: Erythromycin; Roxithromycin; Clarithromycin; Azithromycin; Dirithromycin; and
46/55
2011-04-19 08:56:52
Patent; Schickaneder, Helmut; Nikolopoulos, Aggelos; Hermann, Gesine; US2001/31736; (2001); (A1) English View in Reaxys claim 1 wherein the antibiotic is selected from: Erythromycin; Roxithromycin; Clarithromycin; Azithromycin; Dirithromycin; and Patent; Schickaneder, Helmut; Nikolopoulos, Aggelos; Hermann, Gesine; US2001/31736; (2001); (A1) English View in Reaxys Example Title General Isolation Procedure (Solvent May Form a Two Phase System With Water) General Isolation Procedure (Solvent May Form a Two Phase System With Water) A reaction mixture as obtained in one of the Examples above as specified in TABLE 2 below under "Reaction Example" is cooled to room temperature and treated with 40 ml of solvent as specified in TABLE 2 below under "Solvent", 40 ml of water and 20percent sulfuric acid to obtain a pH of the mixture of ca. 4. The mixture obtained is stirred for ca. 15 minutes and the phases are separated. The aqueous phase obtained is extracted with 25 ml of solvent as specified in TABLE 2 below under "Solvent". The aqueous phase is treated with 20percent sodium hydroxide to obtain a pH 9 and the mixture obtained is stirred for ca. 15 minutes and extracted with 25 ml of solvent as specified in TABLE 2 below under "Solvent". The organic phase is dried over anhydrous sodium sulphate and the sodium sulphate is filtrated off. The organic solvent is evaporated off. Azithromycin in a yield as specified in TABLE 2 below under "Yield (in gram)" in percent of theory as specified in TABLE 2 below under "percent of theory" is obtained. Patent; Biochemie S.A.; US6420537; (2002); (B1) English View in Reaxys Example Name 1 Example Title EXAMPLE 1 EXAMPLE 1 To a solution of 2 g (2.7 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, in 20 ml of acetic acid, there were added 0.03 g (0.38 mmoles) of sodium acetate and 0.5 g of wet 5percent Rh/C (11.25 mg Rh). The mixture was then hydrogenated at a pressure of 70 bar and at 40.deg. C. for 3 hours. At the end of this period, 27 ml of an aqueous solution containing 37percent formaldehyde (0.36 moles) were added under atmospheric pressure and at room temperature, and the mixture hydrogenated at 40 bar and at a temperature of 40.deg. C. for 20 hours. The catalyst was filtered off and the filtrate evaporated until an oil was obtained. To the oil so obtained, 45 ml of water were added, and the pH of the solution was adjusted to 9.3 with 4N NaOH. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 1.2 g of crude azithromycin with a purity of 97percent after recrystallization. Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English View in Reaxys Example Name 2 Example Title EXAMPLE 2 EXAMPLE 2 To a solution of 4 g (5.4 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, dissolved in 20 ml of acetic acid, 1 g wet 5percent Rh/C (22.5 mg Rh) was added. The mixture was hydrogenated at 60 bar and at a temperature of 40.deg. C. for 5 hours. At the end of this period, 22.5 ml of an aqueous solution containing 37percent formaldehyde (0.3 moles) were added under atmospheric pressure and at room temperature, and the mixture was then hydrogenated at 40 bar and at a temperature of 40.deg. C. for 20 hours. The catalyst was filtered off and the filtrate evaporated until an oil was obtained. To this oil, 90 ml of water were added, and the pH of the solution was adjusted to 9.4 with 4N NaOH. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 2 g of crude azithromycin with a purity of 97percent after recrystallization.
47/55
2011-04-19 08:56:52
Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English View in Reaxys Example Name 3 Example Title EXAMPLE 3 EXAMPLE 3 To a solution of 8 g (10.9 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, in 32 ml of acetic acid and 8 ml of water, there were added 8 g of wet 5percent Rh/C (180 mg Rh). The mixture was then hydrogenated at 70 bar and at room temperature for 2 hours. At the end of this period, 40 ml of an aqueous solution containing 37percent formaldehyde (0.54 moles) were added, and the mixture was hydrogenated at 40 bar and at a temperature of 40-45.deg. C. for 20 hours. The catalyst was filtered off, and the pH of the filtrate was adjusted to 9.4 with 4N NaOH. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 7 g of crude azithromycin with a purity of 95percent after recrystallization. Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English View in Reaxys Example Name 4 Example Title EXAMPLE 4 EXAMPLE 4 To a solution of 4 g (5.4 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, in 4 ml of acetic acid and 16 ml of water, were added 4 g of wet 5percent Rh/C (90 mg Rh). The mixture was hydrogenated at 70 bar and room temperature for 2 hours. At the end of this period, 25 ml of an aqueous solution containing 37percent formaldehyde (0.34 moles) was added under atmospheric pressure at room temperature and the mixture was hydrogenated at 40 bar and at a temperature of 40-45.deg. C. for 24 hours. The catalyst was filtered off, and the pH of the filtrate adjusted to 9.4 with 4N NaOH. After stirring for 2 hours at room temperature, the precipitate was filtered off, washed with water, and dried, yielding 2.8 g of crude azithromycin with a purity of 98percent after recrystallization. Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English View in Reaxys Example Name 5 Example Title EXAMPLE 5 EXAMPLE 5 To a solution of 8 g (10.9 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, in 24 ml of acetic acid, there were added 8 g of wet 5percent Rh/C (180 g Rh). The mixture was hydrogenated at 70 bar and at room temperature for 2 hours. At the end of this period, 50 ml of an aqueous solution containing 37percent formaldehyde (0.67 moles) were added under atmospheric pressure at room temperature, and the mixture was hydrogenated at 40 bar and 40-45.deg. C. for 24 hours. The catalyst was filtered off, and the pH of the filtrate was adjusted to 9.5 with 4N NaOH. After stirring for 2 hours at room temperature, the solids were filtered, washed with water, and dried, yielding 6.1 g of crude azithromycin with a purity of 98percent after recrystallization. Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English View in Reaxys Example Name 6 Example Title EXAMPLE 6 EXAMPLE 6 To a solution of 4 g (5.4 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, in 18 ml of acetic acid and 2 ml of water, there were added 2 g of wet 5percent Rh/C (45 mg Rh). The mixture was then hydrogenated at 70 bar and at room temperature for 2 hours. At the end of this period, 35 ml of an aqueous solution containing 37percent formaldehyde (0.47 moles) were added under atmospheric pressure at room temperature, and the pH was adjusted between 3 and 4 with 4N NaOH. The mixture was hydrogenated at 40 bar and at a temperature of 40-45.deg. C. for 24 hours. The catalyst was filtered off, and the pH of the filtrate was adjusted to 9.4 with 4N NaOH. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 2.7 g of crude azithromycin with a purity of 96percent after recrystallization. Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English
48/55
2011-04-19 08:56:52
View in Reaxys Example Name 7 Example Title EXAMPLE 7 EXAMPLE 7 To a solution of 8 g (10.9 mmoles) of the imino ether of erythromycin A, prepared by the usual techniques, in 8 ml of acetic acid and 32 ml of water, there were added 8 g of wet 5percent Rh/C (180 mg Rh). The mixture was then hydrogenated at 70 bar and at 40.deg. C. for 2 hours. At the end of this period, 10 g (0.33 moles) of para-formaldehyde was added under atmospheric pressure at room temperature, and the pH of the reaction mixture was adjusted to 4 with NaOH. Hydrogenation was carried out at a pressure of 40 bar and at a temperature of 40-45.deg. C. for 24 hours. The catalyst was filtered off, and the pH of the reaction mixture was adjusted to 9.2 with NaOH 4N. After stirring for 2 hours at room temperature, the solids were filtered, washed with water, and dried, yielding 4.98 g of crude azithromycin with a purity of 97percent after recrystallization. Patent; Hovione Inter Ltd.; US6013778; (2000); (A1) English View in Reaxys Example Name 3 Example Title N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A EXAMPLE 3 N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A A solution of the crude product of Example 2, comprising N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A desosaminyl-N-oxide and N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A bis-N-oxide (4.36 g), in 150 ml of absolute ethanol was hydrogenated on a Parr apparatus (3.52 kg/m2; 8.0 g 10percent palladium on carbon catalyst; ambient temperature) for 11/4 hours. The catalyst was filtered, and the resulting filtrate was evaporated to dryness, affording a colorless foam (4.3 g). The crude product was taken up in methylene chloride (100 ml) and then stirred with water (100 ml) while the pH of the mixture was adjusted to 8.8. The organic and aqueous layers were separated. The aqueous layer was then extracted twice with 50 ml portions of methylene chloride. The three organic extracts were combined, dried over anhydrous sodium sulfate and evaporated to afford a colorless foam (3.0 g). The entire sample was dissolved in 11 ml of warm ethanol, and water was added until the solution became slightly turbid. Upon standing overnight, 1.6 g of the title product crystallized from solution; m.p.136.deg. C., dec. A recrystallization by the same procedure raised the melting point to 142.deg. C., dec. 1 Hnmr (CDCl3) delta 2.31 [6H, s, (CH3)2 N-], 2.34 STR8 13 Cnmr [CDCl3, (CH3)4 Si internal standard] ppm 178.3 (lactone, C=0), 102.9 and 94.8 (C-3, C-5), 41.6 STR9 40.3 [(CH3)2 -N-]; MS: m/e 590, 432, 158. Patent; Pfizer Inc.; US4474768; (1984); (A1) English View in Reaxys 0.45 g (82.4%) Example Name 1 Example Title N-methyl-11-aza-10-deoxo-10-dihydro erythromycin A EXAMPLE 1 N-methyl-11-aza-10-deoxo-10-dihydro erythromycin A To a solution of 0.54 g (0.000722 mole) of 11-aza-10-deoxo-10-dihydro erythromycin A in 20 ml of CHCl3 there were added, while stirring, 0.0589 ml (0.000741 mole) of formaldehyde (approx. 35percent w./w.) and 0.0283 g (0.000735 mole) of formic acid (approx. 98 to 100percent w./w.). The reaction mixture was stirred for 8 hours while heating under reflux, then cooled to ambient temperature, whereupon there were added 15 ml of water (pH 5.8). The pH of the reaction mixture was adjusted to 5.0 by means of 2N HCl, whereupon the chloroform layer was separated. To the aqueous part there was added 15 ml of CHCl3, the pH of the reaction suspension was adjusted to 7.5 by means of 20percent w./w. of NaOH, the layers were separated and subsequently the aqueous layer was extracted three times with 15 ml of CHCl3. The combined chloroform extracts having a pH of 7.5 were dried over K2 CO3 and evaporated under reduced pressure, yielding 0.45 g (82.4percent) of N-methyl-11-aza-10deoxo-10-dihydro erythromycin A, m.p. 113.deg.-115.deg. C. []D 20 =-37.0 (1percent in CHCl3); M30 =748.
49/55
2011-04-19 08:56:52
Patent; Sour Pliva farmaceutska, kemijska prehrambena i kozmeticka industrija, n.sol.o.; US4517359; (1985); (A1) English View in Reaxys Example Name 5 Example Title 9-Deoxo-9a-methyl-9a-aza-9a-homoerythromycin A PREPARATION 5 9-Deoxo-9a-methyl-9a-aza-9a-homoerythromycin A By the procedure of Example 10 above, title product of the preceding Preparation (21.1 g., 0.0287 moles) was converted to present title product, initially isolated as a white foam, crystallized from hot ethanol/H2 O, 18.0 g., mp 136.deg. C. Patent; Pfizer Inc.; US4526889; (1985); (A1) English View in Reaxys Example Name 5 Example Title N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A EXAMPLE 5 N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A A solution of crude product of Example 2 comprising N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A desosaminyl-N-oxide and N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A bis-N-oxide (10.0 g) in 150 ml of absolute ethanol was hydrogenated on a Parr apparatus [3.52 kg/m2; 15 g of Raney-Nickel catalyst (water-wet sludge); ambient temperature] for 11/2 hours. Work-up as described in Example 3 afforded 8.5 g of the title product, with TLC Rf values identical to those of Example 3. Patent; Pfizer Inc.; US4474768; (1984); (A1) English View in Reaxys Example Name 1 Example Title EXAMPLE 1 EXAMPLE 1 To a solution of 2 g (2.7 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 20 ml of acetic acid, there was added 0.03 g (0.38 mmoles) of sodium acetate and 0.5 g of wet 5percent Rh/C (11.25 mg Rh). The mixture was then hydrogenated at a pressure of 70 bar and at 40.deg.C for 3 hours. At the end of this period, 27 ml of an aqueous solution containing 37percent formaldehyde (0.36 moles) was added under atmospheric pressure and at room temperature, and the mixture hydrogenated at 40 bar and at a temperature of 40.deg.C for 20 hours. The catalyst was filtered off and the filtrate evaporated until an oil was obtained. To the oil so obtained, 45 ml of water was added, and the pH of the solution was adjusted to 9.3 with NaOH 4N. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 1.2 g of crude azithromycin with a purity of 97percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Example Name 2 Example Title EXAMPLE 2 EXAMPLE 2 To a solution of 4 g (5.4 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 20 ml of acetic acid, there was added 1 g of wet 5percent Rh/C (22.5 mg Rh). The mixture was hydrogenated at 60 bar and at a temperature of 40.deg.C for 5 hours. At the end of this period, 22.5 ml of an aqueous solution containing 37percent formaldehyde (0.3 moles) was added under atmospheric pressure and at room temperature, and the mixture was then hydrogenated at 40 bar and at a temperature of 40.deg.C for 20 hours. The catalyst was filtered off and the filtrate evaporated until an oil was obtained. To this oil, 90 ml of water was added, and the pH of the solution was adjusted to 9.4 with NaOH 4N. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 2 g of crude azithromycin with a purity of 97percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Example Name 3 Example Title EXAMPLE 3
50/55
2011-04-19 08:56:52
EXAMPLE 3 To a solution of 8 g (10.9 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 32 ml of acetic acid and 8 ml of water, there was added 8 g of wet 5percent Rh/C (180 mg Rh). The mixture was then hydrogenated at 70 bar and at room temperature for 2 hours. At the end of this period, 40 ml of an aqueous solution containing 37percent formaldehyde (0.54 moles) was added, and the mixture was hydrogenated at 40 bar and at a temperature of 40-45.deg.C for 20 hours. The catalyst was filtered off, and the pH of the filtrate was adjusted to 9.4 with NaOH 4N. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 7 g of crude azithromycin with a purity of 95percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Example Name 4 Example Title EXAMPLE 4 EXAMPLE 4 To a solution of 4 g (5.4 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 4 ml of acetic acid and 16 ml of water, there was added 4 g of wet 5percent Rh/C (90 mg Rh). The mixture was hydrogenated at 70 bar and room temperature for 2 hours. At the end of this period, 25 ml of an aqueous solution containing 37percent formaldehyde (0.34 moles) was added under atmospheric pressure at room temperature and the mixture was hydrogenated at 40 bar and at a temperature of 40-45.deg.C for 24 hours. The catalyst was filtered off, and the pH of the filtrate adjusted to 9.4 with NaOH 4N. After stirring for 2 hours at room temperature, the precipitate was filtered off, washed with water, and dried, yielding 2.8 g of crude azithromycin with a purity of 98percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Example Name 5 Example Title EXAMPLE 5 EXAMPLE 5 To a solution of 8 g (10.9 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 24 ml of acetic acid there was added 8 g of wet 5percent Rh/C (180 mg Rh). The mixture was hydrogenated at 70 bar and at room temperature for 2 hours. At the end of this period, 50 ml of an aqueous solution containing 37percent formaldehyde (0.67 moles) was added under atmospheric pressure at room temperature, and the mixture was hydrogenated at 40 bar and 40-45 .deg.C for 24 hours. The catalyst was filtered off, and the pH of the filtrate was adjusted to 9.5 with NaOH 4N. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 6.1 g of crude azithromycin with a purity of 98percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Example Name 6 Example Title EXAMPLE 6 EXAMPLE 6 To a solution of 4 g (5.4 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 18 ml of acetic acid and 2 ml of water, there was added 2 g of wet 5percent Rh/C (45 mg Rh). The mixture was then hydrogenated at 70 bar and at room temperature for 2 hours. At the end of this period, 35 ml of an aqueous solution containing 37percent formaldehyde (0.47 moles) was added under atmospheric pressure at room temperature, and the pH was adjusted to from 3 to 4 with NaOH 4N. The mixture was hydrogenated at 40 bar and at a temperature of 40-45 .deg.C for 24 hours. The catalyst was filtered off, and the pH of the filtrate was adjusted to 9.4 with NaOH 4N. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 2.7 g of crude azithromycin with a purity of 96percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Example Name 7 Example Title EXAMPLE 7 EXAMPLE 7
51/55
2011-04-19 08:56:52
To a solution of 8 g (10.9 mmoles) of the imino ether of erythromycin A, (prepared by the usual techniques) in 8 ml of acetic acid and 32 ml of water, there was added 8 g of wet 5percent Rh/C (180 mg Rh). The mixture was hydrogenated at 70 bar and at 40.deg.C for 2 hours. At the end of this period, 10 g (0.33 moles) of para-formaldehyde was added under atmospheric pressure at room temperature, and the pH of the reaction mixture was adjusted to 4 with NaOH. Hydrogenation was carried out at a pressure of 40 bar and at a temperature of 40-45 .deg.C for 24 hours. The catalyst was filtered off, and the pH of the reaction mixture was adjusted to 9.2 with NaOH 4N. After stirring for 2 hours at room temperature, the solid was filtered, washed with water, and dried, yielding 4.98 g of crude azithromycin with a purity of 97percent after recrystallization. Patent; HOVIONE INTER LTD.; EP879823; (1998); (A1) English View in Reaxys Similarly at 75percent and 100percent relative humidity, the water content rose rapidly, but was now maintained at even higher levels, 6.6percent and 7.2percent, respectively, for at least 3 days. 1. Use of an antiprotozoal effective amount of: azithromycin; 4-epi-azithromycin; 4-amino-4-deoxy-azithromycin; or 4-epi-4amino-4-deoxy-azithromycin; Patent; PFIZER INC.; EP307128; (1989); (A2) English View in Reaxys Example Name 5 Example 5: Anhydrous Azithromycin;; Azithromycin (500 gm, moisture content = 2.64percent) was dissolved in dichloromethane (8.0 Lit). The solution was heated and the solvent was completely removed under vacuum. Acetonitrile (2.5 Lit) was added to the residue so obtained and the reaction mass was gradually cooled to 15 to 2O0C. The resulting slurry was stirred at 15 to 2O0C for three hours and filtered; the solids so obtained were dried under, vacuum to get anhydrous azithromycin. Yield: 325 gm Purity: 99.62percent (by HPLC) Moisture Content: 0.6percent w/w. in dichloromethane, acetonitrile, Time= 3h, T= 15 - 20 C , Purification / work up Patent; WOCKHARDT LTD; PUROHIT, Manish; MUKARRAM, Siddiqui Mohammad Jaweed; NAITHANI, Pankaj Kumar; POKALWAR, Raj Kumar; SUTARIYA, Prakash Maganlal; WO2007/80507; (2007); (A2) English View in Reaxys Example Name C.4 Example Title Uncoated Azithromycin Pellets COMPARATIVE EXAMPLE 4 Uncoated Azithromycin Pellets Extruded pellets with the following composition were produced in the same manner as Comparative Example 1: Patent; Gruenenthal GmbH; US2010/68290; (2010); (A1) English View in Reaxys Example Name 12 Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
HO O O
OH
Rx-ID: 23252030 View in Reaxys
52/55
2011-04-19 08:56:52
Yield
Conditions & References Example Name 9 Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys Example Name 11 Patent; Biochemie S.A.; US6703372; (2004); (B1) English View in Reaxys Example Name 4 Example Title EXAMPLE 4 EXAMPLE 4 Preparation of azithromycin monohydrate. 5g of crude azithromycin, prepared as described in EP 9803945.4, was dissolved in 37.6 ml of water and 2.4 ml of hydrochloric acid (6N) at a temperature of from 20.deg.C to 25.deg.C. To this solution was added 10 ml of acetone and 2.8 ml of 20percent (w/v) aqueous sodium hydroxide solution to adjust the pH to 9.8. After stirring for 4 hours at a temperature of from 20.deg.C to 25.deg.C the suspension was cooled to from 5.deg.C to 0.deg.C and stirred for 1 hour at this temperature. The resulting solid was collected by filtration, washed with water (3 times 5 ml of water cooled at 5.deg.C) and dried at 35-40.deg.C to give azithromycin monohydrate (4.6g). Patent; HOVIONE INTER LTD.; EP941999; (1999); (A2) English View in Reaxys
2 HCl N N OH OH O O H O H O OH O O O OH HO
Rx-ID: 25429515 View in Reaxys Yield Conditions & References Example Name 1 Example Title Example 1 Example 1 To an azithromycin dihydrate solution (5 g, 0.0064 moles) in isopropanol (20 ml), 2.5 ml of a 18percent hydrogen chloride gas solution in dry isopropanol (0.0124 moles of hydrogen chloride gas) were added dropwise under stirring within 5 minutes at a temperature of 10-15 .deg.C. The resulting reaction mixture was added dropwise to diisopropyl ether (130 ml) under stirring within 30 minutes. The stirring of the reaction mixture was continued for another hour at room temperature, subsequently the precipitate was filtered, washed with cold isopropanol (5 ml) and dried for 5 hours in a vacuum dryer at 40 .deg.C. 5.15 g (98.4percent) of azithromycin dihydrochloride, m.p. 186-192 .deg.C, were obtained. Patent; PLIVA, farmaceutska, kemijska, prehrambena, i kozmeticka industrija dionicko drustvo; EP677530; (1995); (A1) English View in Reaxys Example Name 2 Example Title Example 2 Example 2 To an azithromycin dihydrate solution (5g, 0.0064 moles) in acetone (10 ml), 2.5 ml of a 18percent hydrogen chloride gas solution in dry isopropanol (0.0124 moles of hydrogen chloride gas) were added dropwise under stirring within 5 minutes at a temperature of 10-15 .deg.C. Subsequently, while keeping the same temperature, diisopropyl ether (60 ml) was added dropwise into the reaction mixture within 1 hour.
53/55
2011-04-19 08:56:52
After stirring for 1 hour at the same temperature, the precipitated salt was filtered off. 5.20 g (98.9percent) of azithromycin dihydrochloride were obtained. Patent; PLIVA, farmaceutska, kemijska, prehrambena, i kozmeticka industrija dionicko drustvo; EP677530; (1995); (A1) English View in Reaxys Example Name 4 Example Title Example 4 Example 4 According to the process described in Example 1, from azithromycin monohydrate (2g, 0.0026 moles) dissolved in methanol (8 ml), 1.16 ml of 12.9percent hydrogen chloride gas solution in dry methanol (0.0041 moles of hydrogen chloride gas) and diisopropyl ether (16 ml), 2.10 g (98.5percent) azithromycin dihydrochloride were obtained. Patent; PLIVA, farmaceutska, kemijska, prehrambena, i kozmeticka industrija dionicko drustvo; EP677530; (1995); (A1) English View in Reaxys
N N HO OH OH HO
9-deoxo-9a-aza-9a-methyl-9a-homoerythromy cin A
O
O O O
O OH
Rx-ID: 24149094 View in Reaxys Yield Conditions & References Example Title Preparation of non-crystalline 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. Method A Preparation of non-crystalline 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. Method A 5 g of crystalline azithromycin monohydrate are dissolved in 25 ml of tert-butanol heating at 30.deg. C. This solution is filtered and solidified in a cooling bath. The solvent is sublimed at room temperature and 10-2 mm Hg. The solid obtained is dried (80 mm Hg/40.deg. C.) to yield 5 g of non-crystalline azithromycin. IR (KBr) vmax=3500, 1740, 1470, 1280, 1268, 1257 cm-1 (See FIG. 2) 1H-NMR (CDCl3), 13C-NMR (CDCl3), m/e, TLC and HPLC are identical to those of the previous example percent H2O (K. F.)=3.0percent DSC=See FIG. 3X-Ray Diffraction=See FIG. 4 Patent; Astur-Pharma, S.A.; US6451990; (2002); (B1) English View in Reaxys Example Title Preparation of non-crystalline 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. Method B. Preparation of non-crystalline 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. Method B. 5 g of crystalline azithromycin monohydrate are dissolved in 25 ml of ethanol. The solution is filtered and the solvent evaporated at room temperature and 150 mm Hg. The solid obtained is dried (80 mm Hg/40.deg. C.) to yield 5 g of non-crystalline azithromycin, which analytical data are identical to those of the previous example. Patent; Astur-Pharma, S.A.; US6451990; (2002); (B1) English View in Reaxys
54/55
2011-04-19 08:56:52
3 OH N N HO OH O O O O OH OH OH 10 H 2O 10 O O O
Rx-ID: 23653040 View in Reaxys Yield 89 % Conditions & References Example Name 5 EXAMPLE 5; 100 gms of Azithromycin Monohydrate Isopropanol Clathrate is suspended in Isopropanol 300 ml. The mixture is heated at 50 to 55.deg. C. temp or dissolves the solid completely. In the reaction mixture water (450 ml) is added at the period of 15 to 30 minutes and stirred at six hrs at 20 to 30.deg. C. The resulting product is filtered and washed with (50:50) IPA: water mixture. The product is dried under vacuum (1 mm to 10 mm Hg) at 25-50.deg. C. temp. Yield 89.0 gms (89percent). IPA=3.35percent Water=2.10percent , Purification / work up Patent; ALEMBIC LIMITED; US2006/19908; (2006); (A1) English View in Reaxys
N N HO OH OH O O O O O H O OH HO
O OH H 2O
Rx-ID: 23129436 View in Reaxys Yield Conditions & References Example Name 6.B Patent; PLIVA, d.d.; WO2004/9608; (2004); (A2) English View in Reaxys
55/55
2011-04-19 08:56:52

Reaxys NDF Azithromycin

Enviado por

Dados do documento

Descrição original:

Título original

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Reaxys NDF Azithromycin

Enviado por

Direitos autorais:

Formatos disponíveis

Query

2011-04-19 08h:55m:34s (EST)

Search as: Product, As drawn, No salts, No mixtures

Rx-ID: 23252030 View in Reaxys

Você também pode gostar